




1998

## The Electrophysiological Effects of Acute Thyroid Hormone Exposure on Atrial Myocytes

Jon Paul Fiening  
Loyola University Chicago

Follow this and additional works at: [https://ecommons.luc.edu/luc\\_diss](https://ecommons.luc.edu/luc_diss)

 Part of the [Molecular Biology Commons](#)

---

### Recommended Citation

Fiening, Jon Paul, "The Electrophysiological Effects of Acute Thyroid Hormone Exposure on Atrial Myocytes" (1998). *Dissertations*. 3418.

[https://ecommons.luc.edu/luc\\_diss/3418](https://ecommons.luc.edu/luc_diss/3418)

This Dissertation is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Dissertations by an authorized administrator of Loyola eCommons. For more information, please contact [ecommons@luc.edu](mailto:ecommons@luc.edu).



This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License](#).  
Copyright © 1998 Jon Paul Fiening

LOYOLA UNIVERSITY CHICAGO

THE ELECTROPHYSIOLOGICAL EFFECTS  
OF ACUTE THYROID HORMONE EXPOSURE  
ON ATRIAL MYOCYTES

A THESIS SUBMITTED TO  
THE FACULTY OF THE GRADUATE SCHOOL  
IN CANDIDACY FOR THE DEGREE OF  
MASTER OF SCIENCE

DEPARTMENT OF  
CELL AND MOLECULAR PHYSIOLOGY

BY  
JON PAUL FIENING

CHICAGO, ILLINOIS  
JANUARY 1998

Copyright by Jon Paul Fiening, 1998

All rights reserved.

## **ACKNOWLEDGEMENTS**

I would like to express my sincere thanks to Dr. Stephen Lipsius for his advice, expertise and drive for scientific discovery. His selfless time and devotion has taught me the patience and passion needed for scientific discovery. I am grateful for allowing me the opportunity to discover on my own while always being there for guidance and insight.

I would also like to thank the Faculty of the Physiology Department for their excellence in teaching and research. The open-door environment amongst labs created an ideal environment to grow and develop.

Special thanks to the other members of Dr. Lipsius's Lab, Dr. Yang Gao Wang and Ms. Christine Rechemacher, who have provided advice and technical support without which this research would not have been possible.

Most especially, I want to thank my family for providing for me the support, guidance and trust to allow me to follow my goals and dreams.

## TABLE OF CONTENTS

	<u>Page</u>
ACKNOWLEDGEMENTS.....	iii
LIST OF TABLES.....	vii
LIST OF ILLUSTRATIONS.....	viii
 CHAPTER	
I. INTRODUCTION.....	1
II. LITERATURE REVIEW.....	4
A. Synthesis of Thyroid Hormone.....	4
T <sub>4</sub> /T <sub>3</sub> production in thyroid gland.....	4
Cellular thyroid hormone uptake.....	4
B. Clinical Effects of Hyperthyroidism.....	6
Mechanic.....	7
Electrophysiologic.....	7
Hemodynamic.....	8
Metabolic.....	8
C. Cellular Effects of Hyperthyroidism-Chronic.....	10
Nuclear Receptor Binding.....	10
Contractile Associated Proteins.....	10
α- & β- Myosin Heavy Chain.....	10
SR Ca <sup>2+</sup> -ATPase mRNA.....	11
Phospholamban.....	11
TnI.....	12
Ionic Currents.....	12
I <sub>si</sub> (slow inward calcium current).....	12
I <sub>K</sub> (outward rectifier potassium current).....	12
I <sub>ss</sub> (transient outward potassium current).....	12

Cardiac Inotropic Response.....	13
Action potential duration.....	13
Tension development.....	13
Heart rate.....	13
Vascular Smooth Muscle.....	13
D. Cellular Effects of Hyperthyroidism-Acute.....	14
Plasma Membrane Mediated Actions.....	14
Ionic Currents.....	14
I <sub>K1</sub> (inward rectifier potassium current).....	14
I <sub>Na</sub> (sodium current).....	15
Ca <sup>2+</sup> & Glucose uptake.....	16
SR Ca <sup>2+</sup> -ATPase activity.....	16
Calcium Release Channels (Ryanodine Receptor)...	16
β-adrenergic Receptors.....	17
cAMP levels.....	17
Intracardiac Conduction Time.....	18
Cardiac Contractility.....	18
Vascular Smooth Muscle.....	19
III. METHODS.....	20
A. Single Cell Isolation Procedure.....	20
B. Patch-Clamp Recording Technique.....	21
Ruptured patch recording method.....	21
Nystatin-perforated patch recording method.....	22
C. Action Potential Recording Method.....	24
D. Cell Shortening Measurements.....	24
Video Edge Detector.....	24
E. Electronic equipment.....	24
F. Experimental Voltage Protocols.....	25
Na <sup>+</sup> Current.....	25
Na <sup>+</sup> Channel Steady State Inactivation.....	25
Na <sup>+</sup> Channel Steady State Activation.....	26
Na <sup>+</sup> Channel Recovery from Inactivation.....	26
Ca <sup>2+</sup> Current.....	26
G. Measurements and Data Analysis.....	29
H. Solutions, Drugs and Chemical Reagents.....	29

IV. RESULTS.....	34
A. Effect of Thyroid Hormone on Na <sup>+</sup> Current.....	34
B. Effect of T <sub>3</sub> on Na <sup>+</sup> Channel Kinetics.....	44
C. Effect of T <sub>3</sub> on Ca <sup>2+</sup> Current.....	48
D. Effect of T <sub>3</sub> on Action Potential Properties.....	51
E. Effect of T <sub>3</sub> on Cell Shortening.....	55
V. DISCUSSION.....	59
SUMMARY.....	70
BIBLIOGRAPHY.....	71
VITA.....	79

## LIST OF TABLES

<u>Table</u>	<u>Page</u>
1. Cell Isolation Solutions.....	31
2. Cell Perfusion Solutions.....	32
3. Internal Pipette Solutions.....	33



## LIST OF ILLUSTRATIONS

<u>Figure</u>	<u>Page</u>
1. Thyroid Hormone Chemical Structures.....	5
2. Cellular Patch Clamp Recording Technique.....	23
3. Experimental Voltage Protocols.....	27
4. Effect of $T_3$ on Sodium Current.....	35
5. Effect of $rT_3$ on Sodium Current.....	38
6. Effect of $T_4$ on Sodium Current.....	40
7. Effect of TTX on Sodium Current.....	43
8. Effect of $T_3$ on Sodium Channel Kinetics.....	46
A. Activation/Inactivation	
B. Recovery from Inactivation	
9. Effect of $T_3$ on Calcium Current.....	49
A. L-type $Ca^{2+}$ Current	
B. T-type $Ca^{2+}$ Current	
10. Effect of $T_3$ on Action Potentials @ Room Temperature.....	52
11. Effect of $T_3$ on Action Potentials @ 35°C.....	54
12. Effect of Ryanodine on Action Potentials.....	56
13. Effect of $T_3$ on Cell Shortening.....	57

## CHAPTER I

### INTRODUCTION

Clinically patients who are chronically hyperthyroid experience an increased heart rate, stroke volume, systolic blood pressure, cardiac output and cardiac contractility along with various atrial irregularities including atrial fibrillation (Klein & Ojamaa, 1994; Ridgeway, 1994; Natazawa *et al.*, 1994). Most of the laboratory research to date has been conducted on ventricular tissue investigating the chronic effects of thyroid hormone exposure, that are mediated by nuclear receptors, leading to alterations in specific gene expression (Polikar *et al.*, 1993; Sap *et al.*, 1986; Franklyn & Gammage, 1996; Oppenheimer *et al.*, Samuels & Tsai, 1973). Various researchers have documented an increase in cardiac contractility (Buccino *et al.*, 1967; Howitt *et al.*, 1968) and a decrease in action potential duration (Freedberg *et al.*, 1970) due to alterations in ion channel properties and contractile protein mRNA synthesis/degradation rates (Johnson *et al.*, 1973; Sharp *et al.*, 1985; Franklyn & Gammage, 1996; Meo *et al.*, 1994; Binah *et al.*, 1987; Meo *et al.*, 1995; Ojamaa *et al.*, 1992). The slow inward current ( $I_{si}$ ) (Rubinstein & Binah, 1989), the outward rectifying current ( $I_K$ ) (Rubinstein & Binah, 1989) and the  $Ca^{2+}$  current ( $I_{Ca}$ ) (Binah *et al.*, 1987) all increased with chronic  $T_3$  exposure. Cardiac contractile proteins ( $\alpha$ - &  $\beta$ - MHC) mRNA levels as well as associated excitation-

contraction regulatory proteins (SR  $\text{Ca}^{2+}$ -ATPase, phospholamban, and ryanodine receptors) mRNA synthesis/degradation rates varied with chronic  $\text{T}_3$  exposure. While  $\beta$ -MHC mRNA decreased with chronic  $\text{T}_3$  exposure (Franklyn & Gammage, 1996; Balkman *et al.*, 1992),  $\alpha$ -MHC mRNA increased (Ojamaa *et al.*, 1992; Franklyn & Gammage, 1996; Balkman *et al.*, 1992). SR  $\text{Ca}^{2+}$ -ATPase (Ojamaa *et al.*, 1992; Arai *et al.*, 1991) and ryanodine receptor mRNA increased (Arai *et al.*, 1991) whereas phospholamban mRNA decreased (Seitz *et al.*, 1994) with chronic  $\text{T}_3$  exposure leading to faster cellular contraction rate and an increased rate of cellular relaxation due to increased  $\text{Ca}^{2+}$  SR re-uptake.

Only recently have the acute effects of thyroid hormone exposure been investigated. Initially there was controversy about whether the effects seen after a brief bout of  $\text{T}_3$  exposure were in fact due to different mechanisms from the nuclear mediated effects. Now there is documented proof of plasma membrane  $\text{T}_3$  receptors (Segal, 1989). Previously there has been documented increases in the  $\text{Na}^+$  current in neonatal cardiac myocytes (Harris *et al.*, 1991) and rat ventricular myocytes (Dudley & Baumgarten, 1993) and increases in the cellular  $\text{Ca}^{2+}$  uptake in rat heart slices (Segal, 1990) and the isolated perfused heart (Gøtzsche, 1994) with acute  $\text{T}_3$  exposure. Little is known, however, about the acute effects of  $\text{T}_3$  on atrial muscle cells from the adult heart. It is not known whether the previously documented chronic effects altering cardiac contractility and conduction irregularities are attributable to changes seen during an acute exposure to  $\text{T}_3$ . With previous documented effects of acute  $\text{T}_3$  exposure affecting  $\text{Na}^+$  current (Harris *et al.*,

1991; Dudley & Baumgarten, 1993) and cellular  $\text{Ca}^{2+}$  uptake (Segal, 1990; Gøtzsche, 1994), the present research was conducted to investigate the acute effects of thyroid hormone on atrial muscle cells. These experiments will investigate whether the acute effects of  $\text{T}_3$  exposure are similar to the previously documented chronic effects on cardiac function. Results from this research will provide a greater understanding of the cellular mechanisms present during hyperthyroidism and lead to an understanding of potential arrhythmogenic and therapeutic effects of acute thyroid hormone replacement.

## CHAPTER II


### LITERATURE REVIEW

#### **A. Synthesis of Thyroid Hormone**


**T<sub>4</sub>/T<sub>3</sub> production in the thyroid gland.** The thyroid gland is the source of two major hormones, tetraiodothyronine (T<sub>4</sub>) and triiodothyronine (T<sub>3</sub>). T<sub>3</sub> is considered the biologically active thyroid hormone due to its 10 fold higher affinity for the nuclear thyroid hormone receptor (Berne & Levy, 1993). The synthesis of thyroid hormone occurs within the thyroid gland on thyroglobulin. Within the follicle, thyroglobulin is iodinated to yield both moniodotyrosine (MIT) and diiodotyrosine (DIT) with coupling of mono and diiodotyrosine moieties to form T<sub>4</sub> (DIT + DIT) or T<sub>3</sub> (DIT+ MIT) (Genuth, 1993). Secreted from the thyroid gland, thyroxine (T<sub>4</sub>) constitutes approximately 85-90% of the output with T<sub>3</sub> comprising about 10-15 % and reverse T<sub>3</sub> (rT<sub>3</sub>) accounting for only 1 % (Sypniewski, 1993; Genuth, 1993). The half lives of T<sub>4</sub> and T<sub>3</sub> are 7 and 1.5 days respectively (Sypniewski, 1993). The majority of T<sub>3</sub> available to the body tissue is derived outside of the thyroid gland from the peripheral conversion of T<sub>4</sub> to T<sub>3</sub> by the 5'-monodeiodinase enzyme located primarily in the liver and kidney (Astwood, 1970).

**Cellular thyroid hormone uptake.** Once released into the blood stream, T<sub>4</sub> and T<sub>3</sub> are primarily bound to the blood proteins thyroid-binding globulin, thyroid-binding


Figure 1  
Thyroid Hormone Chemical Structures



T<sub>3</sub> (3,5,3'-Triiodo-L-thyronine)



T<sub>4</sub> (L-Thyroxine)



rT<sub>3</sub> (3,3',5'-Triiodo-L-thyronine)

Thyroid hormone chemical structures.  
(modified from Goodman & Gilman, 1970)

prealbumin, and albumin with only 0.02-0.03% and 0.2-0.3% respectively representing the biologically active free form (Sypniewski, 1993; Genuth, 1993; Astwood, 1970). Two theories of cellular thyroid hormone uptake have been presented. Originally, Lein and Dowben (1991) offered indications that triiodothyronine uptake into the tissue occurred as simple diffusion, which seemed to correlated well with the lipophilic properties of thyroid hormone. Recent research in thyroid hormone uptake provides evidence that there is a saturable, stereospecific, energy dependent processes which is responsible for  $T_3$  uptake in rat skeletal muscle (Pontecorvi & Robbins, 1986). Oppenheimer & Schwartz (1985) provide further evidence of a stereospecific transport of thyroid hormone into the nucleus due to the preferential accumulation of L- $T_3$  versus D- $T_3$  in the intact animal.

Once in contact with the nuclear or plasma membrane receptors, thyroid hormone is able to influence the cell leading to changes in the metabolic, mechanic and electrophysiologic properties.

## **B. Clinical Effects of Hyperthyroidism**

The biological hallmark of abnormal thyroid function is a change in the basal metabolic rate (Klein, 1990). Thyroid hormone acts primarily to stimulate cellular oxygen consumption and substrate utilization (Muller *et al.*, 1994). Hyperthyroidism is characterized by elevated serum levels of  $T_3$  and  $T_4$ , due to either an overproduction of  $T_3$  and  $T_4$  in the thyroid gland, an increased release of thyroid hormone from the thyroid gland or an exogenous administration of thyroid hormone. The pharmacological actions

of thyroid hormone include alterations in cardiovascular function and in metabolism of glucose, fatty acid and protein. Hyperthyroidism has been documented to produce a positive cardiac inotropic as well as chronotropic effect with potential arrhythmogenic effects, such as atrial fibrillation (Ridgeway, 1994; Ito *et al.*, 1994). Cardiovascular actions of  $T_3$  can be attributed to (1) direct effects upon the heart, (2) effects upon the peripheral circulatory system, or (3) interactions with the sympathetic/adrenergic system (Nicod *et al.*, 1993). Cardiovascular manifestations of a sustained elevation in thyroid hormone levels include an increased heart rate, myocardial contractility, stroke volume, systolic blood pressure, cardiac output, a widened pulse pressure and a decreased diastolic blood pressure (Klein & Ojamaa, 1994). Contributing to these cardiovascular affects of  $T_3$  are alterations in ion channel properties and associated contractile protein synthesis/degradation rates.

**Mechanic.** Mechanically, when the heart is placed under a hyperthyroid condition contractility increases. Buccino *et al.* (1967), using cat papillary muscles, found a more rapid rate of tension development with less time to reach peak tension in the muscles from chronic hyperthyroid animals, though the maximum tension developed was not significantly greater than from euthyroid animals. Howitt *et al.* (1968), reported indirect indices of increased contractility in humans by showing a shorter ejection time and increased mean systolic ejection rate, suggesting that ejection velocity was enhanced.

**Electrophysiologic.** Hyperthyroidism effects the electrophysiology of the heart by altering various ionic currents which underlie the generation of the action potential at



the single cell level, effecting the conduction and eventual contractile behavior of the heart organ. Tachycardia associated with hyperthyroidism has been shown to be due to a combination of a decrease in action potential duration coupled with an increased rate of diastolic depolarization in the sinoatrial node pacemaker cells (Marshall, 1973). Freedberg *et al.* (1970), using isolated atria from rabbits, showed that although the resting membrane potential and the height of the action potential did not differ, the duration of the action potential repolarization was shortened in animals who received  $T_4$  for 6 weeks. In hyperthyroid dogs, A-V functional refractory period and conduction time were both significantly shortened as the A-H interval decreased with no change in H-V interval (Goel, 1972).

**Hemodynamic.** Hemodynamically, hyperthyroidism places altered preload and afterload forces upon the heart muscles. Thyroid hormone has been shown to lead to peripheral vasculature relaxation (Klein *et al.*, 1994; Dillman, 1989) with decreased circulation time (Smallridge, 1980). This relaxation was due to the direct effect of thyroid hormone on vascular smooth muscle, without influence from endothelium-derived relaxing factor(s),  $\alpha$ - or  $\beta$ - receptor activation, or muscarinic cholinergic receptor activation (Hidaka *et al.*, 1989). An increased blood volume (Klein, 1994), cardiac filling (Dillman, 1994), stroke volume, heart rate, coronary blood flow and oxygen consumption were also present during hyperthyroidism (Smallridge, 1980).

**Metabolic.** Sustained elevated thyroid hormone levels have been shown to effect intermediary metabolism, stimulating oxygen consumption and oxidation of glucose, fatty

acids and amino acids. Mitochondrial adenine nucleotide translocase proteins and respiratory chain enzymes increased under hyperthyroid conditions in the liver. Glucose metabolism increased with thyroid hormone due to an increased amino acid uptake by the liver, an increased activity of gluconeogenic enzymes and an increased oxygen consumption leading to an increase in ATP supply for many metabolic pathways including glucose production. In liver, fatty acid oxidation ( $\beta$ -oxidation) and ketone body production increased with thyroid hormone. Hyperthyroidism is usually accompanied by a negative nitrogen balance with muscle wasting being an obvious sign but surprisingly heart muscle protein did not decrease but actually increased, due to the multiple factors placed upon the heart muscle under elevated thyroid hormone levels (Seitz *et al.*, 1994).

Due to the clinical manifestations of hyperthyroidism, such as tachycardia, nervousness, and tremors, mimicking a hyperadrenergic state, researchers have investigated whether the response to thyroid hormone resulted from a stimulation of the sympathetic nervous system (Polikar *et al.*, 1993). Plasma levels of catecholamines were normal or low in hyperthyroidism (Coulombe *et al.*, 1976). Williams *et al.* (1977) reported in rats that chronic administration of thyroid hormone up regulated the number of  $\beta$ -adrenergic receptors leading to an increased cardiac catecholamine sensitivity. Therefore the hyperadrenergic state seen in hyperthyroidism suggest a hypersensitivity to catecholamines rather than an increase in sympathetic activity, because plasma catecholamine levels are normal or decreased during hyperthyroidism.

### **C. Cellular Effects of Hyperthyroidism-Chronic**

**Nuclear Receptor Binding.** At the cellular level, it is well recognized that the biologically active thyroid hormone ( $T_3$ ) exerts its action by binding to specific thyroid hormone receptors, a protein product of the cellular erythroblastosis A (*c-erb A*) supergene family, located on the nuclear membrane (Franklyn & Gammage, 1996; Polikar *et al.*, 1993; Sap *et al.*, 1986; Oppenheimer *et al.*, 1972; Samuels & Tsai, 1973). Researchers have discovered binding sites for thyroid hormone on nuclei isolated from atrial and ventricular cardiac muscle (Banerjee *et al.*, 1988), and on liver and kidney tissue (Oppenheimer *et al.*, 1972). Upon thyroid hormone binding to its nuclear receptor with subsequent receptor binding to various enhancer/promoter sequences on DNA, gene transcription is stimulated or inhibited (Franklyn & Gammage, 1996; Polikar *et al.*, 1993; Sap *et al.*, 1986). Changes in the quantity or properties of such proteins that are important in the modulation of cardiac contraction may underlie the contractile changes that accompany hyperthyroidism.

**Contractile Associated Proteins.** It has been shown in rat heart that chronic  $T_3$  exposure induces synthesis of  $\alpha$ -myosin heavy chain (MHC) mRNA while exerting an inhibitory effect on  $\beta$ -MHC synthesis (Franklyn & Gammage, 1996), leading to an increase in myosin  $V_1$  and a decrease in myosin  $V_3$  isoenzymes (Dillman, 1990). In a time course experiment, Balkman *et al.* (1992) showed that hypothyroid rats increased  $\alpha$ -MHC mRNA over time, eventually reaching  $93\% \pm 1\%$  of total MHC mRNA, coupled with a decrease in the  $\beta$ -MHC mRNA levels. Myosin  $V_1$ , composed of 2 MHC  $\alpha$

subunits, has a higher myosin ATPase activity than myosin  $V_3$ , which contains 2 MHC  $\beta$  subunits. The globular head of myosin  $V_1$  with its higher myosin ATPase activity than myosin  $V_3$  resulted in an increased velocity of contraction (Dillman, 1990). This marked thyroid hormone-induced change in myosin isoenzyme predominance was demonstrated in small animals (rats, rabbits) but did not occur to a similar extent in larger species, including the human heart in which  $V_3$  is the major ventricular isoenzyme (Franklyn & Gammage, 1996).

In rabbit skeletal and cardiac muscle chronic  $T_3$  administration increased the steady state levels of cardiac ryanodine receptor mRNA and SR  $Ca^{2+}$ -ATPase mRNA when compared with euthyroid rabbit (Arai *et al.*, 1991). The SR  $Ca^{2+}$ -ATPase functions to regulate the intracellular calcium concentration of the myocyte and therefore affects the rate of  $Ca^{2+}$  release and uptake, affecting the rate of systolic tension development and the diastolic relaxation time (Arai *et al.*, 1991). Ojamaa *et al.* (1992) demonstrated in a heterotropic isografted rat heart that although thyroid hormone required an increased hemodynamic load to increase cardiac protein synthesis, thyroid hormone altered the expression of  $\alpha$ -MHC and SR  $Ca^{2+}$ -ATPase mRNA concentration, increasing them 181 and 208% versus euthyroid animals respectively. SR  $Ca^{2+}$ -ATPase mRNA which had been depressed in hypothyroid when compared with euthyroid rat hearts, responded to  $T_4$  with elevated SR  $Ca^{2+}$ -ATPase mRNA levels reaching 255% of control after 72 hours (Balkman *et al.*, 1992).

Phospholamban, a SR  $Ca^{2+}$ -ATPase regulatory protein, mRNA was decreased in

both hyperthyroidism and hypothyroidism while calsequestrin mRNA levels exhibited no change with thyroid status, indicating that thyroid hormone does not alter the calcium storage capacity to the SR (Seitz *et al.*, 1994).  $T_3$  also has been shown to increase production of mRNA encoding for Na-K ATPase, which is responsible for restoring the Na/K gradients and membrane potential after excitation (Evert, 1996).

In a developmental study, rat ventricular myocyte TnI mRNA levels were higher in euthyroid versus hypothyroid. Upon addition of  $T_3$  to young rats (<28 days) TnI mRNA increased versus control, but the effect was not seen after 87 days of gestation, suggesting that the level of TnI mRNA was more sensitive to thyroid status in younger rats (MacKinnon & Morgan, 1986). Other studies provide further evidence for specific mRNAs being induced by  $T_3$  in a highly tissue specific manner (Shanker *et al.*, 1987).

**Ionic Currents.** Chronic  $T_3$  exposure also effects various ionic currents in cardiac and skeletal muscle. Hyperthyroidism increased the slow inward current ( $I_{si}$ ), shifting the threshold for activation as well as the peak current to more negative potentials when compared with control, while hypothyroidism decreased the  $I_{si}$  current (Rubinstein & Binah, 1989). The outward rectifying current ( $I_K$ ) increased with chronic  $T_3$  exposure but hypothyroidism had little effect on  $I_K$  (Rubinstein & Binah, 1989). The peak calcium current also increased in hyperthyroid ventricular myocytes (Binah *et al.*, 1987). Hypothyroidism, in rat ventricular myocytes, decreased the transient outward potassium current ( $I_{ss}$ ) while hyperthyroidism increased the amplitude of  $I_{ss}$  (Shimoni & Severson, 1996).

**Cardiac Inotropic Response.** Incorporating the ionic current and contractile protein alterations with  $T_3$ , the effect of thyroid hormone on cardiac function has been demonstrated on action potential and cardiac contractile mechanics.  $T_3$  exhibited positive inotropic characteristics leading to a decrease in action potential duration (Johnson *et al.*, 1973; Meo *et al.*, 1994; Binah *et al.*, 1987; Meo *et al.*, 1995) and a decrease in the time to peak tension development (Sharp *et al.*, 1985). In rat ventricular myocytes, heart rate increased as well as the ventricle displayed a faster rate of contraction and relaxation leading to a shortened contraction cycle when compared with euthyroid myocytes. There was no change in maximum tension developed by the ventricle, but the duration of the contraction was shorter. This study concurrently measured the calcium transient which was shorter in duration with  $T_3$  and the rise and decline of the calcium transient which exhibited faster kinetics than in euthyroid cells (MacKinnon & Morgan, 1986).

**Vascular Smooth Muscle.** Thyroid hormone directly effected vascular smooth muscle, leading to vascular relaxation in the presence of the  $\beta$ -receptor blocking drug propranolol, the  $\alpha$ -receptor blocker phentolamine and the muscarinic cholinergic blocking agent atropine. Endothelium-derived relaxing factor(s) could also be ruled out as the mechanism of thyroid hormone induced vascular relaxation as thyroid hormone displayed its effect on tissue in which the endothelium was intact or removed (Ishikawa *et al.*, 1989).

#### **D. Cellular Effects of Hyperthyroidism- Acute**

**Plasma Membrane Mediated Actions.** In the last couple of decades the acute effects of thyroid hormone on skeletal, smooth and cardiac muscle have been investigated. Focus has turned to the possible plasma membrane-mediated effects of thyroid hormone, apart from the documented nuclear membrane-mediated effects seen with chronic thyroid hormone exposure. Characteristically, the plasma membrane-mediated effects of thyroid hormone are prompt in onset (seconds to minutes), independent of new protein synthesis, and are associated with changes in the transmembrane transport of ions and substrates (Segal, 1989). Extranuclear sarcolemmal effects of thyroid hormone include effects on the inward rectifier potassium current (Sakaguchi *et al.*, 1996), the sodium current (Harris *et al.*, 1991; Dudley & Baumgarten, 1993), sugar (2-deoxyglucose) transport (Segal & Ingbar, 1990; Segal, 1989),  $\text{Ca}^{2+}$ -ATPase (calcium pump) activity (Segal *et al.*, 1989; Davis *et al.*, 1983), and calcium release from ryanodine receptors (Connelly *et al.*, 1994). Also shown during acute thyroid hormone infusion has been an effect on cardiac conduction time (Gøtzsche, 1994), contractility (Gøtzsche, 1994; Ririe *et al.*, 1995), and cardiac output (Gøtzsche, 1994). In addition to the plasma membrane mediated actions of acute thyroid hormone exposure, thyroid hormone has been shown to promote extranuclear effects on some cytosol proteins (protein kinases) (Lawerence *et al.*, 1989) and on SR  $\text{Ca}^{2+}$ -ATPase activity (Warnick *et al.*, 1988).

**Ionic Currents.** Ionic currents that modulate various cardiac functions have been investigated during acute thyroid hormone exposure. In ventricular guinea pig myocytes,

Sakaguchi *et al.* (1996) demonstrated an increase in the inward rectifier potassium current ( $I_{K1}$ ) with 1 nM  $T_3$ . At the single channel level thyroid hormone application increased the mean open time ( $P_o$ ) of the inward rectifier potassium channel ( $I_{K1}$ ) due mainly to a decreased interburst duration, with no change in the single channel amplitude or slope conductance. It is known that  $I_{K1}$  is the main contributor to the late phase of action potential repolarization (Ibarra *et al.*, 1991). Therefore, these researchers suggested that thyroid hormone may shorten the action potential duration by enhancement of  $I_{K1}$  (Sakaguchi *et al.*, 1996).

Dudley and Baumgarten (1993) have investigated the effects of acute exposure of thyroid hormone on cardiac sodium channels in rat ventricular myocytes, showing that  $T_3$  (5 or 50 nM) induced an increase in the bursting behavior of the channel without a change in the unitary conductance. Using TAA, which does not bind to nuclear thyroid hormone receptors (De Nayer, 1989), bursting behavior increased similarly to  $T_3$ , indicating that within the experimental time frame  $T_3$  was not mediating its effects through nuclear receptors. They further reported that  $T_3$  only increased channel bursting behavior when applied to the extracellular side of the membrane (Dudley & Baumgarten, 1993).

In neonatal cardiac myocytes, thyroid hormone (5-20 nM) application doubled the peak of the inward sodium current within 2 minutes, eventually plateauing at 4 fold control levels after 4 minutes of hormone application. Sodium current inactivation shifted from a monoexponential decay to a bi-exponential fit in the same time period. Steady state



inactivation of sodium current, though, was unaffected by  $T_3$  (Harris *et al.*, 1991).

**$Ca^{2+}$  & Glucose Uptake.** In rat heart slices, the effect of  $T_3$  (10 pM) on calcium and glucose uptake was investigated. Thyroid hormone acutely increased calcium ( $^{45}Ca$ ) uptake that was blocked with inorganic calcium channel blockers ( $La^{3+}$ ,  $Cd^{2+}$ , and  $Mn^{2+}$ ) (Segal, 1990) and increased 2-deoxyglucose uptake, in the presence of cyclohexamide demonstrating that the effects were independent of new protein synthesis (Segal, 1989). Segal (1990) further demonstrated that the molecular mechanism of action of thyroid hormone was mediated by calcium as the first messenger for the acute plasma membrane mediated effects of sugar uptake. In a whole animal experiment, Gøtzsche (1994) showed that acute  $T_3$  administration to a rat resulted in a significant, reversible decrease in calcium perfusate concentration, which was blocked with the calcium channel blocker, nifedipine, indicating that the thyroid hormone induced calcium flux into the cell might be partly mediated through voltage dependent calcium channels.

**SR  $Ca^{2+}$ -ATPase Activity.** Thyroid hormone has been found to regulate sarcoplasmic reticulum membrane  $Ca^{2+}$ -ATPase activity by nonnuclear mechanisms. SR  $Ca^{2+}$ -ATPase activity determines the rate of calcium reuptake and hence the rate at which myocardial relaxation occurs. In striated muscle, SR  $Ca^{2+}$ -ATPase activity increased with  $T_3$  exposure (Warnick *et al.*, 1988).

**Calcium Release Channels.** Thyroid hormone (250 mM) has also been shown to increase activation of calcium release channels (ryanodine receptor) in skeletal muscle SR at the single channel level in planar lipid bilayers (Connelly *et al.*, 1994). The open

probability ( $P_o$ ) increased significantly in the presence of thyroid hormone. These researchers demonstrated that  $T_3$  produces its effect through a direct activation of the ryanodine receptor in the absence of other cellular components.

**$\beta$ -adrenergic Receptors.** Because the clinical signs of hyperthyroidism mimic a hyperadrenergic state, the acute effects of thyroid hormone on  $\beta$ -adrenergic receptors were investigated in cultured chick cardiac myocytes. Initially (under 2 hours),  $T_3$  (10 nM) application resulted in an increased number of receptors on the cell membrane, which was not influenced by the protein synthesis inhibitor cyclohexamide (20 mM). When colchicine (20 mM) was added to the cultured cells,  $T_3$  did not lead to an increase in  $\beta$ -receptor number indicating that the effects of thyroid hormone initially did not depend upon new protein synthesis but relied on microtubule assembly to promote insertion of already synthesized receptors into the plasma membrane from the cytosol (Vassey *et al.*, 1994).

**cAMP levels.** Levey and Epstein (1968) demonstrated in cat heart homogenates that thyroid hormone ( $5 \times 10^{-6}M$ ) activated adenylyl cyclase leading to cAMP accumulation at levels significantly higher than control animals within 3 minutes. This cAMP accumulation was independent of diminished degradation by phosphodiesterase indicating a direct effect by thyroid hormones on regulating activation of adenylyl cyclase. Also since the effect was produced within 3 minutes, it would suggest that thyroid hormone increased activity due to actual activation of adenylyl cyclase rather than generation of new enzymes because the time frame appears to be too short for new protein synthesis to

occur.

**Intracardiac Conduction Time.** Shahawy *et al.* (1975) demonstrated that acute thyroid hormone exposure in dogs resulted in a decrease in the intracardiac conduction time. During thyroid hormone perfusion the heart rate increased, the A-H interval decreased while the H-V interval remained constant when compared with euthyroid animals. In triiodothyronine treated pigs, cardiac contractility increased significantly after 15 minutes (Gøtzsche, 1994). Cardiac output increased along with contractile force ( $+dP/dt$ ) which was blocked with amiodarone suggesting the mechanism of action of thyroid hormone was by altering the permeability properties of the calcium channel on the sarcolemmal membrane (Gøtzsche, 1994).

**Cardiac Contractility.** In an isolated rat heart, Ririe *et al.* (1995) demonstrated that a bolus injection of  $T_3$  (0.74 nM) was able to increase left ventricle contractility ( $+dP/dt$ ) within 30 seconds with no change in end diastolic pressure.  $T_4$  was unable to increase contractility even at levels 17 times (12.9 nM) the bolus injection of  $T_3$  indicating a specificity for  $T_3$  in mediating the effects of acute hyperthyroidism. The effects of  $T_3$  were transient, with the increased contractility dissipating over a period of 60-90 seconds after drug administration.  $\beta$ -receptor blockade with propranolol (1 mM) did not effect the ability of  $T_3$  to increase contractility, as maximum developed tension with and without  $\beta$ -receptor blockade was  $393 \pm 29$  and  $335 \pm 38$  mmHg/sec, respectively.  $T_3$ , at concentrations that had been shown to increase contractility and even as high as  $10^{-6}$  M, exhibited no effect on cAMP production (Ririe *et al.*, 1995), in contrast to the earlier work

done by Levey and Epstein (1968). At the single cell level, in isolated ventricular myocytes,  $T_3$  caused a dose dependent increase in contractility independent of  $\beta$ -receptor stimulation (Walker *et al.*, 1994).

**Vascular Smooth Muscle.** Hyperthyroidism has been shown to decrease systemic vascular resistance. Since vascular smooth muscle tonic contraction is a major determinant of vascular resistance (Berne & Levy, 1993), the acute effects of thyroid hormone on smooth muscle have been investigated. Thyroid hormone (10-30 mM) relaxed isolated rabbit mesenteric artery smooth muscle strips previously contracted with 50 mM KCl. This relaxation was due to the direct effect of thyroid hormone on vascular smooth muscle, without influence from endothelium-derived relaxing factor(s),  $\alpha$ - or  $\beta$ -receptor activation, or muscarinic cholinergic receptor activation (Ishikawa *et al.*, 1989). In cultured smooth muscle cells, addition of  $T_3$  (0.1 nM) produced a visible relaxation of the cells in 10 minutes (Ojamaa *et al.*, 1994).

## CHAPTER III

### METHODS

#### A. Single Cell Isolation Procedure

Adult cats of either sex, weighing approximately 2 kg were anesthetized with sodium pentobarbital (80 mg/kg; IP). Single atrial muscle cells were isolated according to methods previously reported (Wu *et al.*, 1991; Zhou & Lipsius, 1992,93a,b). To remove the heart a midsternal thoractomy was performed. The heart was quickly attached to a Langendorff perfusion apparatus at the aorta. The heart was perfused for 5 minutes with a Tyrode solution at 37°C until the blood was washed out completely (Table 1, Solution 1). This was followed by a second perfusion of 5 minutes with a  $\text{Ca}^{2+}$ -free Tyrode solution (Table 1, Solution 2) and a final perfusion of 50-60 minutes with a Tyrode solution containing 36  $\mu\text{M}$   $\text{Ca}^{2+}$ , 0.1% albumin, and 0.06% collagenase (Table 1, Solution 3). The enzyme solution was recirculated with a pump. During the enzyme recirculation period, every 10 minutes 27  $\mu\text{M}$   $\text{Ca}^{2+}$  was added to the perfusate to eventually yield a  $\text{Ca}^{2+}$  concentration of approximately 200  $\mu\text{M}$ . The two atria were removed from the heart and separated from one another by cutting through the septal region of the atria. Atrial tissue was cut into small pieces ( $<0.5 \text{ cm}^2$ ) and incubated in

fresh enzyme solution for 15 minutes at 37°C while being agitated in a water bath. The tissue suspension was filtered through a nylon mesh (210  $\mu\text{m}$ ) using Tyrode solution containing 200  $\mu\text{M}$   $\text{Ca}^{2+}$  and 0.1% albumin. After allowing the cells to settle for around 30 minutes, the superfusate was suctioned off and the isolated cells were gradually replaced with and stored at room temperature until use in a HEPES-buffered solution (Table 2, Solution 1).

Cells used for study were transferred to a small tissue bath (0.4 ml) mounted on the stage of an inverted microscope (Nikon Diaphot) and superfused with a modified HEPES Tyrode solution (Table 1, Solution 4). Solution was perfused by gravity at approximately 4 ml/min. Cells selected for study were elongated, exhibited nice striations, and were quiescent.


## **B. Patch-Clamp Recording Technique**

**Ruptured patch recording method.** Cells used for experiments were transferred to a tissue bath (0.4 ml) mounted on the stage of an inverted microscope (Nikon Diaphot). Sodium currents were measured on atrial muscle cells using the ruptured patch whole cell recording technique (Hamill *et al.*, 1981). Pipettes were pulled from borosilicate glass (Sutter Instrument Co.) in a six step process using a horizontal programmable puller (Flaming Brown, model PC 80, Sutter Instrument Co.) Pipettes were fire polished to smooth out the electrode tip by passing current through a platinum wire in close proximity to the pipette tip. Pipettes were first briefly dipped in the pipette solution to fill the tip

and the pipette was backfilled with the same solution (Table 3, Solution 1). Pipettes had internal diameters of 1.0-1.5  $\mu\text{m}$  and when filled with internal solution yielded a final resistance of 3-4  $\text{M}\Omega$  when placed in the perfusion bath. Capacitance and pipette resistance were compensated before recording from each cell. Upon touching the cell membrane, negative pressure was applied to form a gigaseal. After a stable gigaseal was obtained (2-5 minutes) additional suction was applied to rupture the membrane patch. Before patch rupture cells were perfused with HEPES Tyrode solution (Table 2, Solution 1). After patch rupture cells were perfused with a Low  $\text{Na}^+$  Tyrode solution (Table 2, Solution 2).

**Nystatin-perforated patch recording method.** L-type  $\text{Ca}^{2+}$  currents and action potential recordings were measured on atrial muscle cells using the nystatin perforated-patch whole cell recording technique (Horn & Marty, 1988). Nystatin was dissolved in dimethylsulfoxide at a concentration of 50 mg/ml and then added to the internal pipette solution to yield a final concentration of 150  $\mu\text{g/ml}$ . The nystatin containing pipette solution was strongly sonicated so that the nystatin was completely dispersed in the solution leaving to pipette solution a clear pale yellow. Pipettes were pulled from borosilicate glass by a horizontal programmable puller and fire polished. Pipette internal diameter was 1.0-1.5  $\mu\text{m}$  and when filled with internal solution (Table 3, Solution 2) yielded a final resistance of 2-3  $\text{M}\Omega$  when placed in the perfusion bath. Capacitance and pipette resistance were compensated before recording from each cell. After the electrode made contact with the cell surface a slight negative pressure was delivered to form a

Figure 2  
Cellular Patch Clamp Recording Technique



- A. The standard ruptured patch recording technique.  
B. The nystatin-perforated patch recording technique.  
(modified from Horn & Marty, 1998)



gigaseal between the cell and the electrode. Before patch attachment, cells were perfused with HEPES Tyrode solution. After patch seal was established, a High  $\text{Cs}^+$  Tyrode solution (Table 2, Solution 3) was used to perfuse the external cell surface at a temperature of 35°C.

### **C. Action Potential Recording Method.**

Action potentials were elicited by stimulation through the recording electrode in the bridge mode using 2-3 msec voltage pulses. Pulses were generated by an external stimulus (Pulsar 4i Stimulator, Frederick Haer & Co.; Brunswick, Maine) and recorded by computer and magnetic reel to reel tape.

### **D. Cell Shortening Recording Method.**

**Video Edge Detector.** The cells were superfused with HEPES-Tyrode solution (Table 2. Solution 1) at 35°C. The nystatin perforated-patch technique was used to gain access to the cell. A stimulus generated from an external source was applied to the cell through the cell- attached electrode and the cell shortening produced was measured with the use of a video edge detector with data stored by the computer and magnetic reel to reel tape. The spatial resolution of the video edge detector at 400x magnification is 0.015 microns.

### **E. Electronic equipment.**

Ionic currents (discontinuous single electrode voltage clamp) were recorded in the ruptured patch whole cell configuration and nystatin perforated-patch whole cell method with an Axoclamp-2-A amplifier (Axon Instruments, Inc., Foster City, Calif.). Action potentials were recorded in the bridge mode of the Axoclamp-2-A amplifier. Cells were externally stimulated through the recording electrode by a Pusa 4i Stimulator (Frederick Haer & Co., Brunswick, Maine). Cell shortening was measured with a Video Edge Motion Detector (Crescent Electronics; Sandy, Utah). In the voltage clamp mode the sampling rate was 10-12 kHz. Computer software run on a Dell 386 (PCLamp 6.0 program; Axon Instruments, Inc.) was used to generate the voltage clamp protocols as well as record and analyze voltage and ionic current signals. Voltage and ionic currents were sampled by a 12-bit resolution A/D converter (Tecmar Labmaster, Tecmar Inc., Cleveland, OH) with the use of a Dell 386 computer. Data was stored on hard disc and backed up on a bernuilli disk for later analysis.

### **F. Experimental Voltage Protocols.**

**Na<sup>+</sup> Current.** Currents were measured using the ruptured patch whole cell technique (Hamill *et al.*, 1981). Ionic currents were activated from atrial cells by depolarizing clamp steps from a holding potential of -80 mV in 10 mV increments to +50 mV for 80 msec. Two seconds between incremental clamp steps were used to allow from complete channel recovery from inactivation. Peak Na<sup>+</sup> clamp steps were from holding

potential of -80 mV to -40 mV. Peak Na<sup>+</sup> current was measured with respect to steady state current.

**Na<sup>+</sup> Channel Steady State Inactivation.** Channel kinetics were measured using the ruptured patch whole cell technique. Cells were held at -120 mV and clamped in 10 mV increments up to +20 mV for 1 second. Following the initial incremental clamp, the cell was returned to -120 mV for 2 msec, after which the cell was clamped to -40 mV. Steady State inactivation for each cell was normalized using the maximum peak current recorded for that particular cell.

**Na<sup>+</sup> Channel Steady State Activation.** Measured using the ruptured patch whole cell technique. Cells were held at -80 mV and clamped for approximately 2 msec, or a duration not leading to channel inactivation, in 10 mV voltage steps from -80 to +50 mV. After the conditioning prepulse to various voltages, the cell was clamped back to -60 mV and the tail current elicited was measured. Steady state activation was determined by comparing the tail current elicited at each varying prepulse voltage step with the maximum current elicited, yielding a normalized steady state activation curve.

**Na<sup>+</sup> Channel Recovery from Inactivation.** Measured using the ruptured patch whole cell technique. Cells were held at -110 mV and clamped for a conditioning pulse to -40 mV for 1 second. Following the conditioning pulse was a variable time interval (from 0.2 msec to 150 msec) at -110 mV after which the cell was clamped to -40 mV for 50 msec. The test current was compared with the conditioning current ( $I_{\text{test}}/I_{\text{cond}}$ ) at each recovery time to yield a normalized value for each cell.

Figure 3  
Experimental Voltage Protocols






Figure 3  
Experimental Voltage Protocols



**Ca<sup>2+</sup> Current.** Ionic currents were measured with nystatin perforated-patch whole cell recording technique (Horn & Marty, 1988). Cells were held at -40 mV and clamped from -40 to +70 mV for 200 msec in 10 mV voltage steps. Peak  $I_{Ca,L}$  was measured with respect to steady state current.

**Action Potential and Cell Shortening.** Intracellular recordings were obtained with the nystatin perforated patch technique. Cells were stimulated by an external source at variable frequencies at a stimulus amplitude sufficient to generate an action potential. Cell shortening was measure with a video edge detector by following the one edge of the contracting cell. Action potentials and cell shortening was recording on the computer as well as magnetic reel to reel tape.

### **G. Measurements and Data Analysis.**

The membrane capacitance ( $C_m$ ) was measured by delivering a ramp voltage clamp pulse ( $dV/dt=5V/sec$ ) and dividing the half-amplitude of the current jump at the turning point of the ramp pulse by the ramp slope. Whenever possible the currents were normalized in reference to the  $C_m$  of each individual cell to yield current density (pA/pF). Data are presented as means  $\pm$  standard error of the mean (SEM). Paired t-test was used for statistical analysis and differences with p values  $<0.05$  were considered statistically significant.

## **H. Solutions, Drugs and Chemical Reagents.**

All solutions were made on the same day as the experiment from double-deionized water. The solutions used for cell isolated are listed in Table 1. The internal pipette solutions used for standard ruptured patch and nystatin-perforated patch are listed in Table 3.

### **List of drugs and chemical reagents:**

Collagenase (type II, 209 units/mg)

Albumin (Sigma Chemical Company)

Na<sub>2</sub>-ATP (grade 1, Sigma Chemical Company)

Ethyleneglycol-bis-N,N,N',N'-Tetraacetic Acid (Sigma Chemical Company)

Nystatin (Sigma Chemical Company)

Tetrodotoxin (Calbiochem)

4-Aminopyridine (Sigma Chemical Company)

Tetraethylammonium Chloride (Sigma Chemical Company)

Ryanodine (Penick, Lyndhurst, New Jersey)

Verapamil (Sigma Chemical Company)

3,5,3'-Triiodo-L-thyronine (Sigma Chemical Company)

3,3',5'-Triiodo-L-thyronine (Sigma Chemical Company)

3,5,3',5'-Tetraiodothyronine (Sigma Chemical Company)

Thapsigargin (Sigma Chemical Company)

Table 1. Cell Isolation Solutions

	1	2	3	4
	Normal Tyrode	Ca <sup>2+</sup> -free Tyrode	Perfusion Enzyme	HEPES Tyrode
NaCl (mM)	137	137	137	137
KCl (mM)	5.4	5.4	5.4	5.4
CaCl <sub>2</sub> (mM)	1.8	--	0.036	1.8
MgCl <sub>2</sub> (mM)	1.0	1.0	1.0	1.0
NaHCO <sub>3</sub> (mM)	12	12	12	--
NaH <sub>2</sub> PO <sub>4</sub> (mM)	0.6	0.6	0.6	--
Glucose (mM)	11	11	11	11
Albumin (%)	--	--	0.1	--
Collagenase (%)	--	--	0.06	--
HEPES (mM)	--	--	--	5
pH	7.4*	7.4*	7.4*	7.35**

\* Bicarbonate-buffered Tyrode solutions were bubbled with 95% O<sub>2</sub>-5% CO<sub>2</sub> to pH 7.4.

\*\* Hepes-buffered Tyrode solution was titrated with NaOH to pH 7.35.



Table 2. Cell Perfusion Solutions

	1 HEPES Tyrode	2 Low Na <sup>+</sup> Tyrode	3 High Cs <sup>+</sup> Tyrode
NaCl (mM)	137	50	137
KCl (mM)	5.4	5.4	5.4
CaCl <sub>2</sub> (mM)	2.0	2.0	2.0
MgCl <sub>2</sub> (mM)	1.0	1.0	1.0
TEA-Cl (mM)	--	67	--
Verapamil (mM)	--	0.005	--
4-Aminopyridine (mM)	--	2.0	--
CsCl (mM)	--	20	20
Glucose (mM)	11	11	11
HEPES (mM)	5	5	5
pH	7.35*	7.35**	7.35*

\* Hepes-buffered Tyrode solution was titrated with NaOH to pH 7.35.

\*\* Hepes-buffered Low Na<sup>+</sup> Tyrode solution was titrated with CsOH to pH 7.35.

Table 3. Internal Pipette Solutions

	1 Rupture Patch ( $I_{Na}$ )	2 Nystatin Perforated Patch ( $I_{Ca}$ )	3 Nystatin Perforated- Patch (A.P.)
Glutamic Acid (mM)	100	--	--
Cesium Glutamate (mM)	--	100	--
Potassium Glutamate (mM)	--	--	100
MgCl <sub>2</sub> (mM)	1.0	1.0	1.0
KCl (mM)	--	--	40
Na <sub>2</sub> ATP (mM)	4.0	4.0	4.0
EGTA (mM)	10	0.5	0.5
CsCl (mM)	40	40	--
CsOH (mM)	100	--	--
HEPES (mM)	10	10	10
pH	7.20*	7.20*	7.20**

\* Hepes-buffered Low Na<sup>+</sup> pipette solution and Ca<sup>2+</sup> pipette solution were titrated with CsOH to pH 7.20.

\*\* Hepes-buffered pipette solution (A.P.) was titrated with KOH to pH 7.20.

## CHAPTER IV


### RESULTS

To be assured that the  $\text{Na}^+$  current observed in isolated atrial myocytes were reasonable, the quality of the voltage clamp was evaluated. To monitor voltage clamp control two criteria were used. First, the voltage clamp step measured by the electrode was compared with the voltage clamp step generated by the computer to minimize the variation. Second, the current generated did not exhibit a “threshold phenomenon” near the voltage for peak current activation, but rather the current elicited a gradual increase as the clamp steps approached the peak current level. To aid in controlling the large  $\text{Na}^+$  current, the  $[\text{Na}]_o$  was reduced to 50 mM and all the  $\text{Na}^+$  current experiments were conducted at room temperature.

#### **A. Effect of Thyroid Hormone on $\text{Na}^+$ Current.**

Macroscopic  $\text{Na}^+$  current was recorded from isolated atrial cells using the ruptured patch technique. Figure 4A shows the peak inward  $\text{Na}^+$  current elicited from an atrial muscle cell during a depolarizing clamp step from -80 mV to -40 mV under control conditions and when the cell was acutely (5 minutes) perfused with  $\text{T}_3$  (10 nM). Under control conditions the peak inward current was -36.2 pA/pF while after exposure to  $\text{T}_3$  the

Figure 4


Effect of  $T_3$  on Sodium Current in Atrial Myocytes

Effect of  $T_3$  (10 nM) on atrial muscle cells. Panel A shows the peak inward sodium current elicited from a single atrial muscle cell in response to an acute exposure of  $T_3$ . Panel B shows the effect of an acute exposure on 25 cells and upon recovery (R) in 9 cells.

## Figure 4 - continued

Effect of  $T_3$  on Sodium Current in Atrial Myocytes

C




Panel C shows the effect of  $T_3$  (10 nM) on the sodium current-voltage relationship.

peak inward  $\text{Na}^+$  current increased to  $-42.4$  pA/pF. Upon washout of  $\text{T}_3$ , the current decreased to  $-33.4$  pA/pF. In 25 cells tested (Figure 4B) the peak inward  $\text{Na}^+$  current increased 26.1% from  $-42.9 \pm 4.2$  pA/pF under euthyroid conditions to  $-54.1 \pm 4.7$  pA/pF after an acute exposure to  $\text{T}_3$ . In 9 cells, after washout of  $\text{T}_3$  for 5 minutes, the current returned to  $-45.4 \pm 4.3$  pA/pF indicating that  $\text{T}_3$  was able to be virtually removed from the plasma membrane receptors or that by this time in the experiment (25 minutes) the cell had deteriorated such that the  $\text{Na}^+$  current had rundown more even with  $\text{T}_3$  still bound to its receptors.

When the current-voltage relationship (Figure 4C), generated by 10 mV incremental clamp steps from  $-80$  mV to  $+50$  mV (Figure 3A), was investigated in 7 cells, the onset of inward current ( $-60$  mV), the voltage generating maximal inward current ( $-40$  mV) and the reversal potential ( $+41.7$  mV) all showed no variation between control conditions and when  $\text{T}_3$  was applied. The  $\text{Na}^+$  current showed an apparent reversal potential of  $+41.7 \pm 1.5$  mV, close to the theoretical reversal potential value of  $+46.7$  mV calculated using the Nernst equation for a channel strictly passing  $\text{Na}^+$  current, giving indication that the current elicited was the  $\text{Na}^+$  current.

To investigate whether the increase in peak inward  $\text{Na}^+$  current was specific to  $\text{T}_3$  or showed similar responses to the other hormones produced by the thyroid gland,  $\text{rT}_3$  and  $\text{T}_4$  were investigated. Figure 5A shows the current elicited in a single clamp step from  $-80$  mV to  $-40$  mV in an atrial muscle cell in response to exposure to  $\text{rT}_3$  ( $10$  nM). In 3 cells tested (Figure 5B), the peak inward  $\text{Na}^+$  current showed no statistically significant


Figure 5

Effect of  $rT_3$  on Peak Inward Sodium Current  
in Atrial Myocytes

Effect of  $rT_3$  (10 nM) on atrial muscle cells. Panel A shows the effect on the peak inward sodium current upon exposure to  $rT_3$  in a single atrial muscle cell. Panel B summarizes the effect of  $rT_3$  on the peak inward sodium current in 3 cells.

Figure 5 - continued  
Effect of  $rT_3$  on Sodium Current  
in Atrial Myocytes


C



Panel C shows the effect of  $rT_3$  (10 nM) on the sodium current-voltage relationship.




Figure 6  
Effect of  $T_4$  on Peak Inward Sodium Current  
in Atrial Myocytes



Effect of  $T_4$  (10 nM) on atrial muscle cells. Panel A shows the effect on the peak inward sodium current upon exposure to  $T_4$  in a single atrial muscle cell. Panel B summarizes the effect of  $T_4$  on the peak inward sodium current in 3 cells.

Figure 6 - continued  
Effect of T<sub>4</sub> on Sodium Current  
in Atrial Myocytes




Panel C shows the effect of T<sub>4</sub> (10 nM) on the sodium current-voltage relationship.

variation between control ( $-60.9 \pm 1.6$  pA/pF) and  $rT_3$  ( $-59.7 \pm 2.2$  pA/pF). The current-voltage relationship (Figure 5C) corroborated the peak current data, further demonstrating that  $rT_3$  did not alter the threshold for channel activation, the voltage of peak current generation, or the reversal potential, indicating in our experiment design  $rT_3$  failed to produce effects similar to  $T_3$ . Likewise, the effects of  $T_4$  on atrial  $Na^+$  current were investigated. As shown in figure 6A & 6B, the peak inward  $Na^+$  current exhibited no significant change with  $T_4$  (control:  $-58.2 \pm 2.0$  pA/pF vs.  $T_4$ :  $-55.7 \pm 2.2$  pA/pF). Similarly the current-voltage relationship (Figure 6C) did not vary with  $T_4$  application, in its onset of current activation, its voltage of peak current or its reversal potential, giving indication that the increase in  $Na^+$  current was specific to  $T_3$ .

To demonstrate that the current being elicited from the voltage clamp protocol was the “fast”  $Na^+$  current, TTX (tetrodotoxin) along with variations in the holding potential of the cell were employed. Figure 7A demonstrates that 10  $\mu$ M TTX was able to block 95.6% of the current as compared to control conditions ( $-2.2 \pm 0.8$  pA/pF vs.  $-47.9 \pm 5.8$  pA/pF). In figure 7B the holding potential of the atrial muscle cell was varied from -80 mV (HP-80) to -40 mV (a level believed to inactivate the sodium current). When the cell was clamped from these holding potentials to 0 mV the current generated at HP-80,  $-8.4 \pm 0.6$  pA/pF, was nearly completely eliminated at HP-40,  $-0.11 \pm 0.05$  pA/pF. These two results suggest that the current elicited by the voltage protocol is strictly the “fast”  $Na^+$  current.

Figure 7

### Effect of TTX on the Sodium Current in Atrial Myocytes



Demonstration that the current elicited from the voltage clamp protocol (Figure 3A) is the "fast" sodium current. Panel A shows the effect of TTX (10  $\mu$ M) on the current-voltage relationship. Panel B shows the effect of varying the holding potential (HP) of the cell on a single clamp step from HP to 0 mV.

### **B. Effect of $T_3$ on $Na^+$ Channel Kinetics.**

To uncover the possible mechanism responsible for the increase in  $Na^+$  current, channel kinetics were investigated. The steady state properties of  $Na^+$  current inactivation were studied using a standard two-pulse protocol (Figure 3B). First a step of variable amplitude and a duration long enough to activate the  $Na^+$  current were applied. Atrial cells were clamped from prepulses to selected conditioning potentials from a holding potential of -120 mV positive to +20 mV. After repolarization to the holding potential for 2 msec, a test pulse to -40 mV was applied. The current elicited by the test pulse was normalized to that obtained in the absence of a preceding conditioning pulse and compared in the presence and absence of  $T_3$ .

The steady state properties of  $Na^+$  current activation were studied by measuring tail currents (Figure 3C). The atrial cell membrane was depolarized from -80 mV to a conditioning potential for a time long enough to allow the activation process to obtain its steady state value. The duration of the conditioning clamp was short enough so that inactivation did not have time to develop. At the end of the conditioning pulse the membrane was clamped to a fixed test potential and the amplitude of the tail current at the beginning of this step was measured. Atrial cells were held at -80 mV and clamped for approximately 2 msec, or a clamp duration not leading to channel inactivation, in 10 mV voltage steps to +50 mV. After the conditioning prepulse to various voltages, the cell was clamped back to -60 mV and the tail current was measured. Steady state activation was determined by comparing the tail current elicited at each varying prepulse with the


maximum current elicited, yielding a normalized steady state activation curve.

Figure 8A shows inactivation/activation curves in the absence and presence of  $T_3$  (10 nM). In 10 cells tested there was no statistically significant increase in either parameter with  $T_3$ . Data were fitted by curves calculated using the Boltzmann function :  $I/I_{\max} = \{1 + \exp[(V_c - V_{0.5})/k]\}^{-1}$ , where  $V_c$  is the voltage of the conditioning pulse,  $V_{0.5}$  is half maximal voltage, and  $k$  is the slope factor. At -110 mV,  $h_{\infty}$  was  $0.994 \pm 0.006$ ; at -40 it was  $0.002 \pm 0.005$ . The voltage of half-activation was -83.5 mV in control conditions versus -82.5 mV in the presence of  $T_3$ . The slope factor,  $k$ , was 7.1 under control and  $T_3$  conditions. Under control and  $T_3$  conditions, steady state activation had an initial onset of -60 mV and reached a peak channel activation at -20 mV. The “window” current, which is considered to be the steady state component of the “fast”  $Na^+$  current resulting from the crossover of the activation and inactivation curves which govern the opening of the  $Na^+$  channel, did not change with  $T_3$  exposure.

The time course of  $Na^+$  current recovery from inactivation was defined using the two-pulse protocol shown in figure 3D. Cells were held at -110 mV and clamped for a 1 second conditioning pulse to -40 mV. Following the conditioning pulse was a variable time interval (from 0.2 msec to 150 msec) at the holding potential after which the cell was clamped to -40 mV for 50 msec. The test current was compared with the conditioning current ( $I_{\text{test}}/I_{\text{cond}}$ ) at each recovery time.  $Na^+$  channel recovery from inactivation (Figure 8B) was investigated in 6 cells. There was no statistical variation in channel recovery rate in the absence or presence of  $T_3$ . In both cases the channel reached 90% recovery in

Figure 8

# Effect of T<sub>3</sub> on Sodium Channel Kinetics in Atrial Myocytes




Voltage-dependence of activation and inactivation for sodium current. Open symbols represent steady-state activation and inactivation curves for control. Closed symbols represent the steady-state activation and inactivation for T<sub>3</sub> (10 nM). Continuous curves were obtained by fitting the data with a Boltzmann equation.

Figure 8 - continued

### Sodium Channel Recovery from Inactivation in Atrial Myocytes

B



Effect of T<sub>3</sub> (10 nM) on the sodium channel recovery time from inactivation. Test current peak ( $I_{test}$ ) normalized versus conditioning current peak ( $I_{cond}$ ) under control conditions and after an acute exposure to T<sub>3</sub>.



approximately 25 msec.


### **C. Effect of $T_3$ on $Ca^{2+}$ current.**

Other researchers have documented a chronic increase in the L-type  $Ca^{2+}$  channel current in the presence of thyroid hormone (Binah *et al.*, 1987) as well as an acute increase in calcium uptake (Gøtzsche, 1994; Segal, 1989). In this experimental design, in the time demonstrated to increase the  $Na^+$  current (0-15 minutes) there was no increase in the peak  $Ca^{2+}$  current (Figure 9A) or in the current-voltage relationship (Figure 9B). In 7 atrial muscle cells tested the onset of the current, the voltage of peak current, and the reversal potential of the current all remained unchanged when comparing control and  $T_3$  (10 nM).

The T-type  $Ca^{2+}$  current may be influencing the increase seen with  $T_3$  when measuring the  $Na^+$  current. To investigate this possibility,  $NiCl_2$  (50  $\mu M$ ), a specific blocker of the T-type  $Ca^{2+}$  current (Wu & Lipsius, 1990) was perfused. Initially the cell was exposed to  $T_3$  and the voltage protocol used to measure the  $Na^+$  current (Figure 3A) was employed. After an increase in  $Na^+$  current was seen with  $T_3$ ,  $NiCl_2 + T_3$  was perfused and the current was recorded. In 5 atrial cell after 5 minutes of perfusion with  $NiCl_2$  there was no statistically significant decrease in the peak inward  $Na^+$  current (Figure 9C) (Control:  $-45.9 \pm 2.3$  pA/pF,  $T_3$ :  $-55.2 \pm 3.8$  pA/pF,  $T_3 + NiCl_2$ :  $-52.9 \pm 3.0$  pA/pF). These results indicate that the T-type  $Ca^{2+}$  current was not influencing the increase seen in the  $Na^+$  current with exposure to  $T_3$ .

Figure 9


# Effect of T<sub>3</sub> on L-type Calcium Current in Atrial Myocytes



Effect of T<sub>3</sub> (10 nM) on the L-type calcium current in atrial muscle cells. Panel A shows the peak inward calcium current in control, T<sub>3</sub>, and recovery. Panel B shows the current-voltage relationship for the L-type calcium current under control conditions and after acute T<sub>3</sub> exposure.

Figure 9 - continued

Influence of T-type Calcium Current on  
Sodium Current Increase with  $T_3$   
in Atrial Myocytes



Influence of the T-type calcium current on the sodium current increase with  $T_3$  (10 nM) in atrial muscle cells. Sodium current-voltage relationship under control conditions, after an acute exposure to  $T_3$ , after subsequent exposure to  $T_3 + \text{NiCl}_2$  (50  $\mu\text{M}$ ) and after recovery.

#### **D. Effect of T<sub>3</sub> on Action Potential Properties.**


Correlating the changes seen in the Na<sup>+</sup> current data, stimulated (0.5 Hz) atrial muscle cell action potentials were investigated. In figure 10A & B the effect of T<sub>3</sub> on action potentials in a single atrial muscle cell at room temperature were investigated. Exposure to T<sub>3</sub> (10 nM) lead to a gradual “notching” of the plateau phase of the action potential, in 3 of 5 cells tested. Upon withdrawal of T<sub>3</sub>, in all 3 cells, this “notching” disappeared. The resting membrane potential and peak action potential overshoot were unaffected by T<sub>3</sub> exposure. Action potential duration (90% repolarization) decreased with T<sub>3</sub> exposure from  $525.4 \pm 7.0$  msec to  $479.2 \pm 9.0$  msec. Interestingly the duration of 50% repolarization slightly increased with T<sub>3</sub> from  $233.6 \pm 8.0$  msec to  $248.4 \pm 10.4$  msec due probably to the “notching” seen during the plateau phase of the action potential.

Figure 11 shows the effects of T<sub>3</sub> on stimulated (0.5 Hz) atrial muscle cells at 35°C. Exposure to T<sub>3</sub> (10 nM) lead to spontaneous depolarizations which increased in frequency with the length of the T<sub>3</sub> perfusion. In 7 out 10 cells tested, perfusion with T<sub>3</sub> lead to the generation of spontaneous beats. Of the cells that exhibited spontaneous beats, the average time before spontaneous beats developed was  $4.9 \pm 0.9$  minutes with a range from 1 to 8 minutes. After 5 minutes of perfusion at 35°C, the cells exhibited on average  $10.4 \pm 1.4$  extra beats in a 40 second period. Upon withdrawal of T<sub>3</sub> in 5 out of 7 of these cells the spontaneous beats disappeared.

In two series of experiments, the effect of SR load was investigated to determine its effect on the T<sub>3</sub> induced delayed after depolarizations. Ryanodine, an alkaloid that


Figure 10

**A**      Effect of  $T_3$  on Atrial Action Potential  
             @ Room Temperature




Action potential recordings from an atrial muscle cell stimulated at 0.5 Hz at room temperature. Recordings during control,  $T_3$  (10 nM), and recovery.

## Figure 10 - continued

Effect of  $T_3$  on Atrial Action Potential  
@ Room Temperature

Panel B shows individual action potentials in atrial muscle cells stimulated at 0.5 Hz at room temperature. Recordings during control,  $T_3$  (10 nM), and recovery.

Figure 11



Action potential recordings from an atrial muscle cell stimulated at 0.5 Hz at 35 ° C. Recordings during control,  $T_3$  (10 nM), and recovery. Spontaneous beats are indicated by (\*).

opens SR  $\text{Ca}^{2+}$  release channels (Janczeski & Lakatta, 1993) and prevents accumulation of SR  $\text{Ca}^{2+}$  and thapsigargin, an inhibitor of SR  $\text{Ca}^{2+}$  uptake (Rousseau *et al.*, 1987) were tested. Figure 12 shows that the effects of ryanodine on stimulated atrial muscle cells in the presence of  $\text{T}_3$ . In 4 atrial cells demonstrating spontaneous beats with  $\text{T}_3$ , ryanodine ( $1\ \mu\text{M}$ ) in the presence of  $\text{T}_3$  lead to the elimination of the extra beats. Similarly, thapsigargin ( $5\ \mu\text{M}$ ) also eliminated the extra beats in the presence of  $\text{T}_3$  alone (data not shown). During control conditions, resting membrane potential was  $-56.4 \pm 0.5\ \text{mV}$  as compared to  $-55.0 \pm 0.7\ \text{mV}$  when perfused with  $\text{T}_3$ . Likewise the action potential overshoot showed no statistically significant variation with  $\text{T}_3$  (control:  $23.6 \pm 0.2\ \text{mV}$  vs.  $\text{T}_3$ :  $25.5 \pm 1.7\ \text{mV}$ ). These results indicate that by inhibiting the accumulation of SR  $\text{Ca}^{2+}$ , these agents selectively abolished the proarrhythmic effects of  $\text{T}_3$ .


#### **E. Effect of $\text{T}_3$ on Cell Shortening**

Finally the contractile behavior of single atrial cells was investigated (Figure 13). Cell contractile strength was quantified by measuring unloaded cell shortening in response to a stimulus sufficient to generate an action potential. A video edge detector was used to track the edge of one edge of the cell to quantify the degree of cell shortening. Figure 13 depicts simultaneous action potential recordings (A) and cell shortening (B) under control,  $\text{T}_3$ , and recovery conditions. In 5 atrial muscle cells the cell shortening increased  $34.8 \pm 1.6\ \%$  when  $\text{T}_3$  was perfused as compared with control. Upon washout of  $\text{T}_3$  for 5 minutes, contractility returned to cell shortening  $8.4 \pm 1.1\%$  above control



Figure 12


### Effect of Ryanodine on Action Potentials in Atrial Myocytes



Influence of SR load on T<sub>3</sub> (10 nM) induced arrhythmias. Action potentials were recorded from atrial muscle cells at 35° C, under control, T<sub>3</sub>, and after T<sub>3</sub> + Ryanodine (1 μM). Spontaneous beats are indicated by the (\*).

Figure 13

Effect of  $T_3$  on Action Potentials and Cell Shortening in Atrial Myocytes



Panel A shows action potential recordings at 35° C in control,  $T_3$ , and recovery conditions in an atrial muscle cell. Panel B shows simultaneous cell shortening measurements under control,  $T_3$ , and recovery.

levels indicating that  $T_3$  still had lingering effects due probably to slow dissociation of  $T_3$  from the plasma membrane receptors.

## CHAPTER V

### DISCUSSION

The main purpose of the present study was to determine the acute (0-15 minute) effects of thyroid hormone ( $T_3$ ) on atrial muscle cells. Cardiac muscle cells were isolated from the cat atrium and the properties of the  $Na^+$  current, the  $Ca^{2+}$  current, action potentials and cell shortening generated by stimuli were investigated in the presence of thyroid hormone ( $T_3$ ). Investigation into an individual ionic current was accomplished by isolation of a particular current through a specific voltage clamp protocol and by blocking currents other than the one of interest by use of specific channel blocking agents (i.e. 4-aminopyridine, verapamil,  $Ni^{2+}$ ).  $Na^+$  current was measured by the ruptured patch whole cell recording technique to decrease access resistance to the cell while  $Ca^{2+}$  current and action potential recordings were measured with the nystatin-perforated patch technique to minimize cell dialysis of intracellular constituents with the internal pipette solution and to decrease current rundown.

In these experiments,  $T_3$  at a dose (10 nM) comparable with research conducted by other investigators was perfused around the isolated cells to produce the acute hyperthyroid state. In humans the normal circulating serum thyroid hormone ( $T_3$ ) levels

are in the nanomolar range ( $2.33 \pm 0.54$  nM), and patients experience the clinical signs of hyperthyroidism at slightly higher levels ( $5.08 \pm 1.60$  nM)(Galløe *et al.*, 1993). With the biologically active free  $T_3$  levels only 0.2-0.3% of the serum levels (Berne & Levy, 1993), the use of 10 nM in our experiments might at first seem like a high hormone concentration. A number of things must be kept in mind.

First, we are investigating the effects of thyroid hormone *in vitro* and not *in vivo*. There could be other mitigating factors not present in our system which are present in the intact animal (human) where by levels of thyroid hormone near the cell surface might be much greater than blood levels detected by common clinical procedures. In chronic thyroid hormone experiments, researcher have shown a preferential uptake of thyroid hormone into the cell, indicating that the cell can create a concentration gradient with higher concentrations of thyroid hormone inside the cell than outside in the bathing medium (De Nayer, 1989; Pontecorvi & Robbins, 1986; Krenning *et al.*, 1981; Oppenheimer & Schwartz, 1985). Therefore, it is not unreasonable to believe that  $T_3$  bound to the plasma membrane receptors may be at a higher concentration than the free circulating levels in the blood. To date there is no known study looking at the concentration of thyroid hormone bound to the plasma membrane surface in relation to the concentration measured in the blood.

Second, thyroid hormone has been shown to bind to various plastics (Sypniewski, 1993). Since the perfusion apparatus and tubing leading to the cell bath are made from plastic solution reservoirs and polyethylene tubing (PE tubing), it may be possible that

the actual concentration of thyroid hormone at the cell surface might be lower than the concentration of thyroid hormone in the stock perfusion solution.

Third, the cell isolation procedure may have disrupted a portion of the thyroid hormone plasma membrane receptors, requiring a higher concentration of  $T_3$  to cause a noticeable effect on the  $Na^+$  current than would have been needed with the full complement of plasma membrane receptors. Segal and Ingbar (1986) have shown that trypsinization of the membrane can remove the functionality of the plasma membrane receptors. They demonstrated that trypsinization caused attenuation of binding and action of  $T_3$  on the plasma membrane in rat myocytes. So it could be possible that the cell isolation procedure caused a disruption in the normal binding of  $T_3$  with its plasma membrane receptors, requiring an increased concentration of  $T_3$  to lead to a functional change upon binding to the plasma membrane receptors. Also, since the extracellular  $Na^+$  concentration was reduced by  $1/3$ , to decrease the magnitude of the  $Na^+$  current so the electrode could follow the voltage clamp step, the concentration of  $T_3$  required to show a significant effect on the  $Na^+$  current might need to be higher than during *in vivo* condition when the  $[Na]_o$  is the typical 137 mM.

Characteristically, the plasma membrane-mediated effects of thyroid hormone are prompt in onset (seconds to minutes), thereby being independent of influencing new protein synthesis/degradation rates, and are associated with changes in the transmembrane transport of ions and substrates (Segal, 1989). In chronic hyperthyroidism, thyroid hormone binds to nuclear thyroid hormone receptors (*c-erb A*) altering gene

transcription, leading to changes in protein synthesis/degradation rates. Shanker *et al.* (1987), investigating the response of individual mRNAs to  $T_3$ , showed that in all but one translational product responsive to  $T_3$  ( $n=13$ ), the time require for induction was on the order of at least a couple of hours. In the translational product demonstrating the most rapid response to  $T_3$ , "spot 72b", within one hour of  $T_3$  exposure, levels rose to 2.6 fold those of control. Oppenheimer demonstrated that this lag time between thyroid hormone application and response in mRNA levels was as short as 20 minutes for the appearance of the cytoplasmic mRNA for the protein termed "spot 14" (Oppenheimer, 1985). Still, one must remember that formation of mRNA is just one of the first few steps of protein synthesis. Before this up regulated mRNA level leads to an up regulated protein level affecting cell functional properties, protein translation, modification, translocation and possible membrane insertion must take place, all requiring additional time.

Further support for the action of  $T_3$  not mediating its effects through a nuclear mechanism in our experimental design, comes from research conducted by Banerjee *et al.* (1988), who showed that nuclear receptors for thyroid hormone are lower in atrial tissue versus ventricular tissue. They showed that the binding capacity for  $T_3$  nuclear receptors in the atrium was considerably lower than found in the ventricle. Maximum binding capacity was  $170 \pm 20$  fmol/mg DNA for ventricular nuclei vs.  $55 \pm 10$  fmol/mg DNA for atrial muscle cell nuclei (Banerjee *et al.*, 1988). In our experiments, cyclohexamide was not used to block protein synthesis, but due to the short time interval (under 15 minutes and in most cases under 10 minutes) between initial exposure to  $T_3$  and

measurable effect on  $\text{Na}^+$  current as well as the lower nuclear  $\text{T}_3$  receptor number in atrial versus ventricular tissue, we are confident that the increase in the  $\text{Na}^+$  current is not working through nuclear receptors up regulating protein synthesis rates but rather through a plasma membrane mediated mechanism.

In the present experiments thyroid hormone ( $\text{T}_3$ ) was shown to acutely increase the  $\text{Na}^+$  current in atrial myocytes. Using the ruptured patch technique which dialyses the cell with the internal pipette solution,  $\text{Na}^+$  current increased (26.1%) within 10-15 minutes. In 11 control cells, the  $\text{Na}^+$  current ran down less than 10% ( $-44.3 \pm 4.5$  pA/pF to  $-39.8 \pm 4.1$  pA/pF) over the time demonstrated to increase  $\text{Na}^+$  current with  $\text{T}_3$  in other cells. Therefore, in actuality the  $\text{Na}^+$  current increase with  $\text{T}_3$  is really an underestimate of the true magnitude of the effect of  $\text{T}_3$  on  $I_{\text{Na}}$ . Other groups have shown a similar increase in macroscopic  $\text{Na}^+$  current in neonatal myocytes (Craelius *et al.*, 1989) and an increase in single  $\text{Na}^+$  channel bursting behavior in ventricular myocytes (Dudley and Baumgarten, 1993) with  $\text{T}_3$  exposure. Upon washout of  $\text{T}_3$ , in 9 cells tested,  $\text{Na}^+$  current returned to levels slightly above initial control levels, indicating either that  $\text{T}_3$  was able to be removed from the plasma membrane receptors of the cells or that by this time (around 25 minutes) into the experiment the cells were deteriorating at a rate sufficient to decrease the magnitude of the  $\text{Na}^+$  current.

The acute increase in  $\text{Na}^+$  current was shown to be specific to  $\text{T}_3$  as  $\text{T}_4$  and  $\text{rT}_3$ , other hormones produced by the thyroid gland, exhibited no effect on the  $\text{Na}^+$  current. In experiments similar to these, Sakaguchi *et al.* (1995) demonstrated that  $\text{T}_3$  acutely



increased the inward rectifier potassium current ( $I_{K1}$ ) but  $rT_3$  did not potentiate the  $I_{K1}$  current, even partially inhibiting the effect of  $T_3$  on increasing  $I_{K1}$ . In contrast with our results, other researchers have demonstrated an effect of  $T_4$  on isolated cardiac cells on the expression of SR mRNA protein (Arai *et al.*, 1991),  $Na^+$ - $Ca^{2+}$  exchanger expression (Boerth & Artman, 1996) and cardiac conduction (Shahawy *et al.*, 1975) though primarily the effect was seen in chronic  $T_4$  exposure where peripheral conversion, by 5'-monodeiodinase, could still occur from  $T_4$  to  $T_3$ .

To investigate the mechanism by which  $T_3$  is generating an increase in the  $Na^+$  current,  $Na^+$  channel kinetics were investigated. Both the steady state activation and steady state inactivation curves did not change with  $T_3$  indicating that there was no alteration in the gating mechanism of the channel with  $T_3$ . In an individual isolated current, the decay of the peak  $Na^+$  current showed similar kinetics as control. In contrast to these findings, Craelius *et al.* (1989), found the decay from peak  $Na^+$  current slowed with an acute  $T_3$  exposure. In our findings the recovery of the channel from inactivation showed no difference with  $T_3$ . Because the ruptured patch technique of cellular recording was used, cellular constituents in the cytoplasm were dialyzed away removing their potential influence on the gating mechanism of the channel. But since the increase in  $Na^+$  current was also demonstrated with the rupture patch technique, the lack of cellular constituents did not influence the effect of  $T_3$  on increasing the  $Na^+$  current indicating that a cytosolic second messenger is probably not involved in the upregulation of the  $Na^+$  current with  $T_3$ . The lack of alterations in the sodium channel kinetics with  $T_3$  indicate

that  $T_3$  is not altering the voltage sensor of the channel or the ability of the channel to recover from the inactivated state.

For the macroscopic  $\text{Na}^+$  current to increase, the number of functional  $\text{Na}^+$  channels ( $N$ ) could increase, the open probability of an individual channel ( $P_o$ ) could increase, or the current ( $I$ ) passing through an individual channel could increase. The proposed mechanism by which  $T_3$  is increasing the macroscopic  $\text{Na}^+$  current is by increasing the open probability of the channel. Previously, in single channel recordings, Dudley and Baumgarten (1993) showed in ventricular tissue that single channel current did not increase with  $T_3$  but rather there was an increase in the bursting behavior of the channel. This does not discount the chance that  $T_3$  may also be increasing the number of functional  $\text{Na}^+$  channels, but due to the time frame (minutes) associated between application of  $T_3$  and the measured cellular response, it seems unlikely that new channels are inserted into the membrane at such a fast rate.

It could be possible that  $T_3$  is acting to “turn on”  $\text{Na}^+$  channels already in the plasma membrane and thereby increasing the macroscopic current. Sen & Cui (1992) showed in ventricular myocytes that  $T_3$  ( $1 \times 10^{-8} \text{M}$ ) acutely increased the TTX-sensitive  $I_{\text{Na}}$ . When GTP was loaded into the cells, the onset of increase in  $I_{\text{Na}}$  with  $T_3$  occurred sooner and lead to a greater increase in the peak  $\text{Na}^+$  current level. This effect was abolished when the cells were pretreated with pertussis toxin, giving indication that PTX sensitive G proteins may play an important role in the molecular mechanism underlying the regulation of  $\text{Na}^+$  channels by  $T_3$ . Therefore  $T_3$  may be acting through membrane-

delimited PTX sensitive G proteins (Wickman & Clapham, 1995) to activate  $\text{Na}^+$  channels, leading to an increased macroscopic  $\text{Na}^+$  current.

Segal and Götze showed that  $\text{T}_3$  acutely increased calcium uptake into the cell. Segal (1989) demonstrated that thyroid hormone acutely increased calcium ( $^{45}\text{Ca}^{2+}$ ) uptake in thymocytes that was blocked with inorganic calcium channel blockers, while Götze (1994) showed in a whole animal experiment that  $\text{T}_3$  decreased calcium perfusate concentration (i.e. increased cellular calcium uptake) which was blocked with the calcium channel blocker, nifedipine. In chronic hyperthyroidism Binah *et al.* (1987) showed that peak  $\text{Ca}^{2+}$  current increased in ventricular myocytes. In contrast with these results, in atrial myocytes  $\text{T}_3$  failed to elicit a different response in the  $\text{Ca}^{2+}$  current than under control conditions. In the time demonstrated to increase the  $\text{Na}^+$  current (0-15 minutes) there was no increase in the  $\text{Ca}^{2+}$  current peak amplitude, nor a shift in the current-voltage relationship of the channel in response to  $\text{T}_3$ , indicating that the cellular effects of  $\text{T}_3$  in these experiments were not influenced by changes in the L-type  $\text{Ca}^{2+}$  current.

The T-type  $\text{Ca}^{2+}$  current could also be influenced by  $\text{T}_3$ . To investigate this possibility, recordings were performed on cells in the presence and absence of  $\text{Ni}^{2+}$  (50  $\mu\text{M}$ ), a specific blocker of the T-type  $\text{Ca}^{2+}$  current (Wu & Lipsius, 1990). The increase in  $\text{Na}^+$  current demonstrated with  $\text{T}_3$  was not decreased by perfusion of the cell with  $\text{T}_3$  and  $\text{Ni}^{2+}$  giving indication that the T-type  $\text{Ca}^{2+}$  current was not involved in the acute cellular response to  $\text{T}_3$ . Even if the T-type  $\text{Ca}^{2+}$  current influenced the current increase with  $\text{T}_3$ , because the T-type  $\text{Ca}^{2+}$  current is so small in atrial myocytes,  $-1.0 \pm 0.06 \text{ pA/pF}$

(Wu & Lipsius, 1990), the T-type  $\text{Ca}^{2+}$  current would have to increase at least 5-6 fold to account for the approximately 10 pA/pF increase (-42.9 to -54.1 pA/pF) seen in the current with  $\text{T}_3$ .

Correlating the cellular changes in the macroscopic  $\text{Na}^+$  current with the functional properties of cardiac muscle cells, the effects of  $\text{T}_3$  on atrial muscle cell action potential and contractile strength were investigated. At room temperature, acute  $\text{T}_3$  exposure caused a decrease in the action potential duration. The plateau phase of the action potential exhibited a “notching” effect indicating a secondary increase in net inward current generated. Typically during the plateau phase of the action potential current influx is equal to current outflux, hence generating the plateau in the voltage recording. Sharp *et al.* (1985) showed a similar phenomenon of “double spikes” in the action potential recordings in the presence of chronic hyperthyroidism which was eliminated by the calcium channel blocker D-600, suggesting that the current responsible for this second depolarization was mediated by a voltage dependent  $\text{Ca}^{2+}$  conductance. The current responsible for “notching” seen in our experiments was not fully investigated but thoughts are that it may be an increased  $\text{Ca}^{2+}$  influx through the  $\text{Na}^+$ - $\text{Ca}^{2+}$  exchanger.

When the same atrial cells were raised to 35°C, this “notching” was no longer observable, probably due to the faster cellular repolarization at 35°C. Instead the cells developed spontaneous depolarizations between the stimulated beats. As the length of the perfusion with  $\text{T}_3$  increased the frequency of the spontaneous beats also increased. When  $\text{T}_3$  was removed from the perfusion solution, these spontaneous beats disappeared.

To investigate the mechanism responsible for the development of the spontaneous beats, ryanodine and thapsigargin were perfused along with  $T_3$ . Ryanodine and thapsigargin are both pharmacological compounds which inhibit the SR from accumulating  $Ca^{2+}$ , thereby preventing SR  $Ca^{2+}$  load (Janczewski & Lakatta, 1993; Rousseau *et al.*, 1987). Ryanodine (1  $\mu$ M) and thapsigargin (5  $\mu$ M), when perfused with  $T_3$  in cells exhibiting spontaneous beats with  $T_3$  alone, eliminated the arrhythmogenic effects of  $T_3$ . Therefore, these results imply that the spontaneous beats associated with  $T_3$  application resulted from an increase in SR  $Ca^{2+}$  load. Kass *et al.* (1977) detailed evidence consistent with the idea that an oscillatory release of  $Ca^{2+}$  from internal stores is the primary event underlying development of aftercontractions (i.e. early after depolarization and delayed after depolarizations). As the SR gradually increased its  $Ca^{2+}$  load with  $T_3$  application, occasional spontaneous releases of  $Ca^{2+}$  from the SR occurred leading at first to spontaneous subthreshold contractions, eventually leading to the generation of full spontaneous action potentials. Upon washout of  $T_3$ , as the SR  $Ca^{2+}$  load returned to normal levels, these spontaneous contractions subsided.

Finally the contractile behavior of isolated atrial cells were investigated. Contractility was quantified by measuring cell shortening in response to a stimulus sufficient to elicit an action potential. Upon the addition of  $T_3$ , within 15 minutes contractility increase  $34.8 \pm 1.6$  %. Similar increases in tension/contractile development have been seen with acute  $T_3$  exposure in experiments ranging from isolated muscle cells (Snow *et al.*, 1992, Mager *et al.*, 1992), to the isolated perfused heart (Tielens *et al.*,

1996), to the intact animal (Gøtzsche, 1994). Contractility is believed to increase with increased total cytosolic  $[Ca^{2+}]$  (Bers, 1991). Therefore, if more  $Ca^{2+}$  is released from the SR during each stimulus due to a greater  $Ca^{2+}$  load, a larger contraction will develop.

## SUMMARY

These results support clinical findings seen in chronically hyperthyroid patients who traditionally present themselves with classic symptoms of increased heart rate, stroke volume, cardiac output and cardiac contractility along with potential atrial irregularities including atrial fibrillation (Klein & Ojamaa, 1994; Ridgeway, 1994; Natazawa *et al.*, 1994). The present experiments suggest the possible cellular mechanism responsible for the development of some of these symptoms originates from an increased  $\text{Na}^+$  influx through the TTX-sensitive “fast”  $\text{Na}^+$  channel. These results demonstrate that  $\text{T}_3$  increases intracellular  $\text{Na}^+$  concentration by increasing influx through the TTX-sensitive “fast”  $\text{Na}^+$  channels. The L-type  $\text{Ca}^{2+}$  current was not shown to increase in response to an acute exposure of  $\text{T}_3$ . In previous work,  $\text{T}_3$  was shown to increase the Na/Ca exchange current ( $I_{\text{Na/Ca}}$ ) (Wang & Lipsius unpublished result). Therefore the rise in intracellular  $\text{Na}^+$ , through the TTX-sensitive  $\text{Na}^+$  channel, is believed to stimulate Na/Ca exchange to raise intracellular  $\text{Ca}^{2+}$  concentration. This elevation in intracellular  $\text{Ca}^{2+}$  loads the sarcoplasmic reticulum (SR) with  $\text{Ca}^{2+}$ . With this augmentation in cellular calcium load, contractility increases as more calcium is released from internal stores during each stimulated beat. Overload of the SR with  $\text{Ca}^{2+}$  has been shown to lead to the development of  $\text{Ca}^{2+}$ -mediated delayed after depolarizations and spontaneous activity (Kass *et al.*,

## BIBLIOGRAPHY

1. Arai M, Otsu K, MacLennan DH, Alpert NR, Periasamy M: Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins. *Circulation Research* 1991; **69**: 266-276.
2. Astwood EB: Thyroid and Antithyroid Drugs, in Goodman LS and Gilman A (eds): *The Pharmacological Basis of Therapeutics (4th Edition)*. London, Collier-MacMillan, 1970, pp 1466-1500.
3. Balkman C, Ojamaa K, Klein I: Time course of the in vivo effects of thyroid hormone on cardiac gene expression. *Endocrinology* 1992; **130**: 2001-2006.
4. Banerjee SK, Ulrich JM, Kaldor GJ: Nuclear thyroid hormone receptors in rabbit heart: Reduced triiodothyronine binding in atrium compared with ventricle. *Circulation Research* 1988; **63**: 267-271.
5. Berne RM, Levy MN: *Physiology*. St. Louis, Mosby Year Book, 1993.
6. Bers DM: *Excitation-Contraction Coupling and Cardiac Contractile Force*. Dordrecht, The Netherlands, Kluwer Academic Publishers, 1991.
7. Binah O, Rubinstein I, Gilat E: Effects of thyroid hormone on the action potential and membrane currents of guinea pig ventricular myocytes. *Pflügers Archive* 1987; **409**: 214-216.
8. Boerth SR, Artman M: Thyroid hormone regulates Na<sup>+</sup>-Ca<sup>2+</sup> exchanger expression during postnatal maturation and in adult rabbit ventricular myocardium. *Cardiovascular Research* 1996; **31**: E145-E152.
9. Buccino RA, Spann JF, Pool PE, Sonnenblick EH, Braunwald E: Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. *The Journal of Clinical Investigation* 1967; **46**: 1669-1682.



10. Connelly TJ, El-Hayek R, Sukhareva M, Coronado R: L-thyroxine activates the intracellular  $\text{Ca}^{2+}$  release channels of skeletal muscle sarcoplasmic reticulum. *Biochemistry and Molecular International* 1994; **32**: 441-448.
11. Coulombe P, Dussault JH, Walker P: Plasma catecholamine concentrations in hyperthyroidism and hypothyroidism. *Metabolism* 1976; **25**: 973-979.
12. Cui G, Sen L:  $\text{T}_3$  increases  $\text{Na}^+$  current in adult guinea-pig ventricular myocytes and possible role of GTP-binding proteins. *Circulation* 1992; **86**: I-564.
13. Davis FB, Davis PJ, Blas SD: Role of calmodulin in thyroid hormone stimulation in vitro of human erythrocyte  $\text{Ca}^{2+}$ -ATPase activity. *Journal of Clinical Investigation* 1983; **71**: 579-586.
14. De Nayer P: Thyroid hormone action at the cellular level. *Hormone Research* 1989; **26**: 48-57.
15. Dillman WH: Biochemical basis of thyroid hormone action in the heart. *The American Journal of Medicine* 1990; **88**: 626-630.
16. Dillman WH: Diabetes and thyroid-hormone-induced changes in cardiac function and their molecular basis. *Annual Review Medicine* 1989; **40**: 373-394.
17. Dillman WH, Hartong R: Molecular action of thyroid hormone in the myocardium, in Braveman LE, Eber O, Langsteger W (eds): *Heart and Thyroid*. Wien, Blackwell-MZV, 1994, pp 10-15.
18. Dudley SC, Baumgarten CM: Bursting of cardiac sodium channels after acute exposure to 3,5,3'-Triiodo-L-thyronine. *Circulation Research* 1993; **73**: 301-313.
19. Evert ME: Effect of thyroid hormone on contractility and cation transport in skeletal muscle. *Acta Physiological Scandinavia* 1996; **156**: 325-333.
20. Franklyn JA, Gammage MD: Thyroid disease: Effect on cardiovascular function. *Trends Endocrinology Metabolism* 1996; **7**: 50-54.
21. Freedberg AS, Papp JG, Vaughan Williams EM: The effect of altered thyroid state on atrial intracellular potentials. *Journal of Physiology* 1970; **207**: 357-369.
22. Genuth S: The thyroid gland, in Berne RM and Levy MN (eds): *Physiology*. Chicago, Mosby Year Book, 1993, pp 932-948.

23. Goel BG, Hanson CS, Han J: A-V conduction in hyper- and hypothyroid dogs. *American Heart Journal* 1972; **83**: 504-511.
24. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. The Macmillan Company. Collier-Macmillan Limited, London. 1970.
25. Göttsche LBH: Acute increases in cardiac performance after triiodothyronine: Blunted response in amiodarone-treated pigs. *Journal of Cardiovascular Pharmacology* 1994; **23**: 141-148.
26. Göttsche LBH: L-triiodothyronine acutely increases  $\text{Ca}^{2+}$  uptake in the isolated perfused rat heart. Changes in L-type  $\text{Ca}^{2+}$  channels and  $\beta$ -receptors during short and long term hyper- and hypothyroidism. *European Journal of Endocrinology* 1994; **130**: 171-179.
27. Hamill OP, Marty A, Neyer E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. *Pflügers Archive* 1981; **391**: 85-100.
28. Harris DR, Green WL, Craelius W: Acute thyroid hormone promotes slow inactivation of sodium current in neonatal cardiac myocytes. *Biochimica et Biophysica Acta* 1991; **1045**: 175-181.
29. Horn M, Marty A: Muscarinic activation of ionic currents measured by a new whole-cell recording method. *Journal of General Physiology* 1988; **92**: 145-159.
30. Howitt G, Rowlands DJ, Leung DY, Logan WFE: Myocardial contractility, and the effects of beta-adrenergic blockade in hypothyroidism and hyperthyroidism. *Clinical Science* 1968; **34**: 485-495.
31. Ibarra J, Morley GE, Delmar M: Dynamics of the inward rectifier  $\text{K}^{+}$  current during the action potential of guinea pig ventricular myocytes. *Biophysical Journal* 1991; **60**: 1534-1539.
32. Ishikawa T, Chijiwa T, Hagiwara M, Mamiya S, Hidaka H: Thyroid hormones directly interact with vascular smooth muscle strips. *Molecular Pharmacology* 1989; **35**: 760-765.
33. Janczewski AM, Lakatta EG: Thapsigargin inhibits  $\text{Ca}^{2+}$  uptake, and  $\text{Ca}^{2+}$  depletes sarcoplasmic reticulum in intact cardiac myocytes. *American Journal of Physiology* 1993; **265**: H517-H522.

34. Johnson PN, Freedberg AS, Marshall JM: Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits. *Cardiology* 1973; **58**: 273-289.
35. Kass RS, Lederer WJ, Tsien RW, Weingart R: Role of calcium ions in transient inward currents and aftercontractions induced by strophanthidin in cardiac purkinje fibers. *Journal of Physiology* 1978; **281**: 187-208.
36. Klein I: Thyroid hormone and the cardiovascular system. *The American Journal of Medicine* 1990; **88**: 631-637.
37. Klein I, Ojamaa K: Thyroid disease and the systemic vascular system, in Braverman LE, Eber O, Langsteiger W (eds): *Heart and Thyroid*. Wien, Blackwell-MZV, 1994, pp 16-21.
38. Lawrence WD, Schoenl M, Davis PJ: Stimulation in vitro of rabbit erythrocyte cytosol phospholipid-dependent protein kinase activity. *Journal of Biological Chemistry* 1989; **264**: 4766-4768.
39. Levey GS, Epstein SE: Activation of cardiac adenyl cyclase by thyroid hormone. *Biochemical and Biophysical Research Communications* 1968; **33**: 990-995.
40. MacKinnon R, Morgan JP: Influence of the thyroid state on the calcium transients in ventricular muscle. *Pflügers Archive* 1986; **407**: 142-144.
41. Meo SD, Piro MC, Venditti P, Leo TD: Effect of thyroid state on cardiac electrical activity of the frog *rana esculenta*. *General and Comparative Endocrinology* 1995; **100**: 162-169.
42. Meo SD, Rosaroll PM, Piro MC, Leo TD: Electrophysiological properties of the hyperthyroid rat heart. *Archives Internationales de Physiologies de Biochimie et de Biophysique* 1994; **102**: 153-159.
43. Nakazawa H, Fukuyama N, Ishikawa N, Noh J, Sugino K, Ozaki O, Ito K: Timing of spontaneous reversion of atrial fibrillation to sinus rhythm and efficacy of cardioversion on persistent atrial fibrillation, in Braverman LE, Eber O, Langsteiger W (eds): *Heart and Thyroid*. Wien, Blackwell-MZV, 1994, pp-72-75.
44. Ojamaa K, Balkman C, Klein I: Acute effects of triiodothyronine on arterial smooth muscle cells. *The Annals of Thoracic Surgery* 1994; **56**: S61-S67.

45. Ojamaa K, Samarel AM, Kupfer JM, Hong C, Klein I: Thyroid hormone effects on cardiac gene expression independent of cardiac growth and protein synthesis. *American Journal of Physiology* 1992; **263**: E534-E540.
46. Oppenheimer JH: Thyroid hormone action at the nuclear level. *Annals of Internal Medicine* 1985; **102**: 374-384.
47. Oppenheimer JH, Koerner D, Schwartz HL, Surks MI: Specific nuclear triiodothyronine binding sites in rat liver and kidney. *Journal of Clinical Endocrinology and Metabolism* 1972; **35**: 330-333.
48. Polikar JA, Burger AG, Scherre U, Nicod P: The thyroid and the heart. *Circulation* 1993; **87** (no. 5): 1435-1441.
49. Ridgeway EC: Cardiac consequences of subclinical hyperthyroidism, in Braverman LE, Eber O, Langsteger W (eds): *Heart and Thyroid*. Wien, Blackwell-MZV, 1994, pp 60-66.
50. Ririe DG, Butterworth JF, Royster RL, MacGregor DA, Zaloga GP: Triiodothyronine increases contractility independent of  $\beta$ -adrenergic receptors or stimulation of cyclic-3',5'-adenosine monophosphate. *Anesthesiology* 1995; **82**: 1004-1012.
51. Rousseau E, Smith JS, Meissner G: Ryanodine modifies conductance and gating behavior of single  $\text{Ca}^{2+}$  release channel. *American Journal of Physiology* 1987; **22**: C364-C368.
52. Rubinstein I, Binah O: Thyroid hormone modulates membrane current in guinea-pig ventricular myocytes. *Naunyn-Schmiedeberg's Archive Pharmacologie* 1989; **340**: 705-711.
53. Sakaguchi Y, Cui G, Sen L: Acute effects of thyroid hormone on inward rectifier potassium channel currents in guinea pig ventricular myocytes. *Endocrinology* 1996; **137**: 4744-4751.
54. Samuels HH, Tsai JS: Thyroid hormone action in cell-culture: Demonstration of nuclear receptors in intact cells and isolated nuclei. *Proceedings of the National Academy of Science* 1973; **70**: 3488-3492.
55. Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H, Vennstrom B: The *c-erb-A* protein is a high-affinity receptor for thyroid hormone. *Nature* 1986; **324**: 635-640.

56. Segal J: Acute effect of thyroid hormone on the heart: An extranuclear increase in sugar uptake. *Journal of Molecular and Cellular Cardiology* 1989; **21**: 323-334.
57. Segal J: Calcium is the first messenger for the action of thyroid hormone at the level of the plasma membrane: First evidence for an acute effect of thyroid hormone on calcium uptake in the heart. *Endocrinology* 1990; **126**: 2693-2702.
58. Segal J: Action of the thyroid hormone at the level of the plasma membrane. *Endocrine Research* 1989; **15** (4): 619-649.
59. Segal J, Hardiman J, Ingbar H: Stimulation of calcium-ATPase activation by 3,5,3'-tri-iodothyronine in rat thymocyte plasma membranes. *Biochemistry Journal* 1989; **261**: 749-754.
60. Segal J, Ingbar Sh: 3,5,3'-Tri-iodothyronine enhances sugar transport in rat thymocytes by increasing the intrinsic activity of the plasma membrane sugar transport. *Journal of Endocrinology* 1990; **124**: 133-140.
61. Seitz HJ, Dummmler K, Muller S: Role of thyroid hormone on intermediary metabolism-from liver to heart, in Braverman LE, Eber O, Langsteger W (eds): *Heart and Thyroid*. Wien, Blackwell-MZV, 1994, pp 46-49.
62. Seppet EK, Kolar F, Dixon IMC, Hata T, Dhalla NS: Regulation of cardiac sarcolemmal  $\text{Ca}^{2+}$  channels and  $\text{Ca}^{2+}$  transporters by thyroid hormone. *Molecular and Cellular Biochemistry* 1993; **129**: 145-159.
63. Shahawy M, Stefadouros MA, Carr AA, Conti R: Direct effect of thyroid hormone on intracardiac conduction in acute and chronic hyperthyroid animals. *Cardiovascular Research* 1975; **924**: 524-531.
64. Shanker R, Neeley WE, Dillman WH: Time course of response of individual messenger RNAs in the rat heart of  $\text{T}_3$ . *Journal of Molecular and Cellular Cardiology* 1987; **19**: 595-601.
65. Sharp NA, Neel DS, Parsons RL: Influence of thyroid hormone levels on the electrical and mechanical properties of rabbit papillary muscle. *Journal of Molecular and Cellular Cardiology* 1985; **17**: 119-132.
66. Shimoni Y, Severson DL: Thyroid status and potassium currents in rat ventricular myocytes. *American Journal of Physiology* 1996; **268**: H567-H583.

67. Smallridge RC: Thyroid hormone effects on the heart, in *Heart and Heart-Like Organs*. Academic Press, Inc, 1980, pp 93-160.
68. Snow TR, Deal MT, Connelly TS, Yokoyama Y, Novitzky D: Acute inotropic responses of rabbit papillary muscle to triiodothyronine. *Cardiology* 1992; **80**: 112-117.
69. Sypniewski E: Comparative pharmacology of the thyroid hormone. *The Annals of Thoracic Surgery* 1993; **56**: S2-S8.
70. Tielens ET, Forder JR, Chatham JC, Marrelli SP, Ladenson PW: Acute L-triiodothyronine administration potentiates inotropic responses to  $\beta$ -adrenergic stimulation in the isolated perfused rat heart. *Cardiovascular Research* 1996; **32**: 306-310.
71. Vassey R, Yin YL, Perrot GY: Acute effect of  $T_3$  on  $\beta$ -adrenoceptors of cultured chick cardiac myocytes, in Braveman LE, Eber O, Langsteger W (eds): *Heart and Thyroid*. Wien, Blackwell-MZV, 1994, pp 165-168.
72. Walker JD, Crawford Fa, Mukherjee R, Zile MZ, Spinale FG: Direct effects of acute administration of 3,5,3'-Triiodo-L-thyronine on myocyte function. *The Annals of Thoracic Surgery* 1994; **58**: 851-856.
73. Warnick Pr, Davis FB, Cody V, Davis PJ: Stimulation in vitro of rabbit skeletal muscle sarcoplasmic reticulum  $Ca^{2+}$ -ATPase activity by thyroid hormone and bipyridines. *Proceedings of the 70th Annual Meeting of the Endocrine Society, New Orleans, LA* 1988; abstract: 356.
74. Wickman K, Clapham DE: Ion channel regulation by G proteins. *Physiological Reviews* 1995; **75**: 865-885.
75. Williams LT, Lefkowitz RJ: Thyroid hormone regulation of  $\beta$ -adrenergic receptor number. *The Journal of Biological Chemistry* 1977; **252**: 2787-2789.
76. Wit AL, Rosen MR: Afterdepolarizations and triggered activity, in Fozzard HA, Jennings RB, Haber E & Katz AM (eds): *The Heart and Cardiovascular System*. New York, Raven Press, 1986, pp 1449-1490.
77. Wu J, Lipsius SL: Effect of extracellular  $Mg^{2+}$  on T- and L-type  $Ca^{2+}$  currents in single atrial myocytes. *American Journal of Physiology* 1990; **259**: H1842-H1850.

78. Wu J, Vereecke J, Carmeliet E, Lipsius SL: Ionic currents activated during hyperpolarization of single right atrial myocytes from cat heart. *Circulation Research* 1991; **68**: 1059-1069.
79. Zhou Z, Lipsius SL: Na-Ca exchange current in latent pacemaker cells isolated from cat right atrium. *Journal of Physiology* 1993a; **466**: 263-285.
80. Zhou Z, Lipsius SL: Properties of the pacemaker current ( $I_f$ ) in latent pacemaker cells isolated from cat right atrium. *Journal of Physiology* 1992; **453**: 503-523.
81. Zhou Z, Lipsius SL: Effect of isoprenaline on  $I_f$  current in latent pacemaker cells isolated from cat right atrium: ruptured patch vs. perforated patch whole-cell recording methods. *Pflügers Archive* 1993b; **423**: 442-447.

## **VITA**

The author, Jon Paul Fiening, was born on July 24, 1971 in Springfield, Virginia.

He grauate cum laude from University School in Hunting Valley, Ohio in 1989. In August of that year he enrolled at Grinnell College, Grinnell, Iowa. During his undergraduate years, he majored in Biology while competing for 4 years on the collegiant swim team. In May of 1993 he recieved his Bachelor of Arts in Biology. In August of 1994 he enrolled in graduate school at Loyola University of Chicago in the Physiology Department.

The author has conducted his research under the direction of Dr. Stephen L. Lipsius.



## THESIS APPROVAL SHEET

The thesis submitted by Jon Paul Fiening has been read and approved by the following committee:

Stephen L. Lipsius, Ph.D., Director  
Professor  
Department of Physiology  
Loyola University of Chicago

Allen M. Samarel, M.D.  
Professor  
Department of Medicine and Physiology  
Research Director, Cardiovascular Institute  
Loyola University of Chicago


Michael Fill, Ph.D.  
Associate Professor  
Department of Physiology  
Loyola University of Chicago

Lothar A. Blatter, M.D., Dr. Med  
Assistant Professor  
Department of Physiology  
Loyola University of Chicago

The final copies have been examined by the director of the thesis and the signature which appears below verifies the fact that any necessary changes have been incorporated and that the thesis is now given final approval by the committee with reference to content and form.

This thesis is therefore accepted in partial fulfillment of the requirements for the degree of Master of Science.

9-16-97  
Date

  
\_\_\_\_\_  
Director's Signature